WO2007067494A1 - Compositions de films topiques pour la liberation d’actifs - Google Patents

Compositions de films topiques pour la liberation d’actifs Download PDF

Info

Publication number
WO2007067494A1
WO2007067494A1 PCT/US2006/046269 US2006046269W WO2007067494A1 WO 2007067494 A1 WO2007067494 A1 WO 2007067494A1 US 2006046269 W US2006046269 W US 2006046269W WO 2007067494 A1 WO2007067494 A1 WO 2007067494A1
Authority
WO
WIPO (PCT)
Prior art keywords
film
emulsion
water soluble
composition
agent
Prior art date
Application number
PCT/US2006/046269
Other languages
English (en)
Inventor
Garry L. Myers
Richard H. Fuisz
Original Assignee
Monosol Rx, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monosol Rx, Llc filed Critical Monosol Rx, Llc
Priority to CA002630261A priority Critical patent/CA2630261A1/fr
Priority to JP2008544421A priority patent/JP2009518405A/ja
Priority to EP06844795A priority patent/EP1971312A1/fr
Priority to AU2006322050A priority patent/AU2006322050A1/en
Publication of WO2007067494A1 publication Critical patent/WO2007067494A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q9/00—Preparations for removing hair or for aiding hair removal
    • A61Q9/02—Shaving preparations
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/04—Detergent materials or soaps characterised by their shape or physical properties combined with or containing other objects
    • C11D17/041—Compositions releasably affixed on a substrate or incorporated into a dispensing means
    • C11D17/042—Water soluble or water disintegrable containers or substrates containing cleaning compositions or additives for cleaning compositions
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C11D3/22—Carbohydrates or derivatives thereof
    • C11D3/222—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C11D3/22—Carbohydrates or derivatives thereof
    • C11D3/222—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
    • C11D3/225—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin etherified, e.g. CMC
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/37—Polymers
    • C11D3/3703—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3707—Polyethers, e.g. polyalkyleneoxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/594—Mixtures of polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2001/00—Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as moulding material
    • B29K2001/08—Cellulose derivatives
    • B29K2001/12—Cellulose acetate

Definitions

  • the invention relates to rapidly dissolving, self-supporting films and methods of their preparation.
  • the films contain a topical agent that is evenly distributed throughout the film.
  • the skin is the largest organ in the human body. Typically, the skin requires cosmetic care to maintain it in good condition, and medicinal treatment to cure it when it exhibits symptoms of a disorder. Personal care products and medicinal agents that are administered topically are generally known as topical agents.
  • topical agents One concern when administering topical agents is the ease with which these agents can be applied to the skin.
  • topical agent is dispensed from a bottle or tube onto the fingers or palm of a hand, and applied manually to the skin.
  • a consumer is
  • Films may be used as a delivery system to carry active ingredients such as drugs, pharmaceuticals, and the like.
  • active ingredients such as drugs, pharmaceuticals, and the like.
  • films and the process of making drug delivery systems therefrom have suffered from a number of unfavorable characteristics that have not allowed them to be used in practice.
  • Films that incorporate a pharmaceutically active ingredient are disclosed in expired U.S. Patent No. 4,136,145 to Fuchs, et al. ("Fuchs"). These films maybe formed into a sheet, dried and then cut into individual doses.
  • the Fuchs disclosure alleges the fabrication of a uniform film, which includes the combination of water soluble polymers, surfactants, flavors, sweeteners, plasticizers and drugs. These allegedly flexible films are disclosed as being useful for oral, topical or external use.
  • Fuchs examples include application of the films to mucosal membrane areas of the body, including the mouth, rectal, vaginal, nasal and ear areas. Examination of films made in accordance with the process disclosed in Fuchs, however, reveals that such films suffer from the aggregation or conglomeration of particles, i.e., self-aggregation, making them inherently non-uniform. This result can be attributed to Fuchs' process parameters, which although not disclosed likely include the use of relatively long drying times, thereby facilitating intermolecular attractive forces, convection forces, air flow and the like to form such agglomeration.
  • agglomerates randomly distributes the film components and any active present as well.
  • a small change in the dimensions of the film would lead to a large difference in the amount of active per film.
  • portions of the film may be substantially devoid of any active. Since sheets of film are usually cut into unit doses, certain doses may therefore be devoid of or contain an insufficient amount of active for the recommended treatment. Failure to achieve a high degree of accuracy with respect to the amount of active ingredient in the cut film can be harmful to the patient. For this reason, dosage forms formed by processes such as Fuchs, would not likely meet the stringent standards of governmental or regulatory agencies, such as the U.S. Federal Drug Administration (“FDA”), relating to the variation of active in dosage forms. Currently, as required by various world regulatory authorities, dosage forms may not vary more than 10% in the amount of active present.
  • FDA U.S. Federal Drug Administration
  • Such processes also run the risk of exposing the active, i.e., a drug, or vitamin C, or other components to prolonged exposure to moisture and elevated temperatures, which may render it ineffective or even harmful.
  • the conventional drying methods themselves are unable to provide uniform films.
  • the length of heat exposure during conventional processing often referred to as the "heat history", and the manner in which such heat is applied, have a direct effect on the formation and morphology of the resultant film product. Uniformity is particularly difficult to achieve via conventional drying methods where a relatively thicker film, which is well- suited for the incorporation of a drug active, is desired.
  • Conventional drying methods generally include the use of forced hot air using a drying oven, drying tunnel, and the like.
  • the difficulty in achieving a uniform film is directly related to the rheological properties and the process of water evaporation in the film- forming composition.
  • a high temperature air current such as a film- forming composition passing through a hot air oven
  • the surface water is immediately evaporated forming a polymer film or skin on the surface. This seals the remainder of the aqueous film-forming composition beneath the surface, forming a barrier through which the remaining water must force itself as it is evaporated in order to achieve a dried film.
  • the film frequently collapse around the voids resulting in an uneven film surface and therefore, non-uniformity of the final film product. Uniformity is still affected even if the voids in the film caused by air bubbles do not collapse. This situation also provides a nonuniform film in that the spaces, which are not uniformly distributed, are occupying area that would otherwise be occupied by the film composition.
  • the films are made through a film-forming process, such as reverse roll coating, extrusion, or casting and a controlled, and a desirably rapid, drying process which serves to maintain the uniform distribution of non- self-aggregated components.
  • a film-forming process such as reverse roll coating, extrusion, or casting and a controlled, and a desirably rapid, drying process which serves to maintain the uniform distribution of non- self-aggregated components.
  • the production occurs without the necessary addition of gel formers or polyhydric alcohols and the like which appear to be required in the products and for the processes of prior patents, such as the aforementioned Horstmann and Zerbe patents.
  • the films will also incorporate compositions and methods of manufacture that substantially reduce or eliminate air in the film, thereby promoting uniformity in the final film product.
  • the present invention provides a film and a method of forming same.
  • the film can be divided into equally sized units having substantially equal amounts of each compositional component present. This advantage is particularly useful because it permits large area films to be initially formed, and subsequently cut into individual units without concern for whether each unit is compositionally equal.
  • the films of the present invention have particular applicability as delivery systems for topical active agents because each film unit will contain the proper amount of the topical active agent.
  • topical agent is meant to encompass active agents that are applied to a particular surface area.
  • a topical agent is applied to an area of the skin.
  • the topical agent may be applied to mucosal areas of the body, such as the oral, vaginal and anal areas of the body.
  • a topical agent is applied to a hard surface, such as a particular surface area in need of cleaning.
  • a self-supporting film includes a water soluble polymer composition including polyethylene oxide and a saccharide-based polymer.
  • the film also includes a topical agent.
  • the film is desirably substantially dissolvable when exposed to a wetting agent, such as water.
  • a wetting agent such as water.
  • Contacting the film with the wetting agent permits the topical agent to be dissolved or dispersed out of the film.
  • the topical agent may then be applied to a particular surface area, such as an area of the skin.
  • the present invention also provides a substantially dissolvable, self-supporting film that includes (i) a water soluble polymer composition including at least one saccharide-based polymer; and (ii) a hair shampoo.
  • a substantially dissolvable, self-supporting film that includes (i) a water soluble polymer composition including at least one saccharide-based polymer; and (ii) a hair conditioner.
  • a substantially dissolvable, self-supporting film that includes (i) a water soluble polymer composition including at least one saccharide-based polymer; and (ii) a sunscreen.
  • the present invention provides a substantially dissolvable, self-supporting film that includes (i) a water soluble polymer composition including at least one saccharide- based polymer; and (ii) an antibacterial hand soap. Furthermore, this invention provides a substantially dissolvable, self-supporting film that includes (i) a water soluble polymer composition including at least one saccharide-based polymer; and (ii) an insect repellant.
  • a substantially dissolvable, self-supporting film that includes (i) a water soluble polymer composition including at least one saccharide-based polymer; and (ii) a moisturizing cream.
  • the present invention further provides a substantially dissolvable, self-supporting film that includes (i) a water soluble polymer composition including at least one saccharide-based polymer; and (ii) a shaving cream or gel.
  • this invention provides a substantially dissolvable, self-supporting film that includes (i) a water soluble polymer composition including at least one saccharide-based polymer; and (ii) an antibiotic.
  • a substantially dissolvable, self-supporting film that includes (i) a water soluble polymer composition including at least one saccharide-based polymer; and (ii) a dish detergent.
  • Each of the films of the present invention maybe divided into smaller individual film units which may be sized and packaged to provide dosage units for consumption.
  • a method of making a self- supporting film unit includes the steps of combining a polar solvent, a topical agent and a water soluble polymer composition comprising polyethylene oxide and at least one saccharide-based polymer to form a material with a uniform distribution of these components.
  • This material is then formed into a film and fed onto the top side of a substrate surface having top and bottom sides. Heat is applied to the bottom side of the substrate surface in order to dry the film.
  • the dried film is then divided into individual film units.
  • the polymer may be selected in order to provide a viscosity that maintains the non-self- aggregating uniform heterogeneity.
  • Techniques may also be used to form the film, including reverse roll coating, extrusion, deposition into molds, and other techniques.
  • a dispenser is also provided that includes individual film units of the present invention.
  • the film units may be optionally stacked in a dispenser or in a roll.
  • a further aspect of the present invention provided is a method of delivering a topical agent.
  • This method includes providing a dry film, which at least partially solubilizes when wetted, the film comprising (i) a water soluble polymer composition including polyethylene oxide and a saccharide-based polymer; and (ii) a topical agent.
  • the method also includes contacting the film with a wetting agent that dissolves out the topical agent; and applying the dissolved topical agent to a surface area in need of the topical agent.
  • the present invention also provides a system for applying a topical agent.
  • the system includes a topical agent contained in a water soluble polymeric film comprising polyethylene oxide and a saccharide-based polymer.
  • the system also includes a solvent for dissolving the film.
  • the solvent is provided for direct contact with the film to cause the topical agent to be dissolved or dispersed out of the film, whereby the topical agent can be applied to a surface area in need thereof.
  • the system may further include an applicator for applying the topical agent to the surface area in need thereof.
  • the present invention provides a composition including a solid water soluble polymeric matrix; and a plurality of lipophilic droplets dispersed within the matrix, the composition forming a liquid/liquid emulsion when exposed to water.
  • the film includes a solid water soluble polymeric matrix having dispersed therein a plurality of lipophilic droplets formed from an emulsion composition.
  • the present invention further provides methods of preparing emulsion compositions.
  • One method of preparing an emulsion composition includes providing an aqueous- based emulsion; and converting the aqueous-based emulsion into a non-aqueous dry emulsion, wherein the dry emulsion is in the form of a self-supporting film. The method further includes dissolving the film with an aqueous solvent, thereby reforming the aqueous- based emulsion.
  • Another method of preparing an emulsion composition includes providing a solid water soluble polymeric film having dispersed therein a plurality of lipophilic droplets; and adding water to dissolve the film, thereby forming an emulsion.
  • the invention provides a method of preparing a film for delivery of an active.
  • the method includes preparing a composition including at least one water soluble polymer; a polar solvent; and an emulsion composition that includes the active; and forming a film from the prepared composition.
  • the method further includes drying the film by a process whereby a plurality of lipophilic droplets including the active become dispersed within the film.
  • the method includes preparing a composition including at least one water soluble polymer; a polar solvent; and an emulsion composition. The method also includes drying the
  • composition to form a dry emulsion including lipophilic droplets dispersed within a solid water soluble polymeric matrix.
  • the present invention further provides a method of delivering an emulsion
  • the method includes providing a solid water soluble polymeric matrix having dispersed therein a plurality of lipophilic droplets.
  • the method further includes exposing the polymeric matrix to a wetting agent to dissolve the polymeric matrix, thereby forming an emulsion; and applying the emulsion to a surface area in need thereof.
  • Another aspect of the present invention relates to a system for applying an emulsion.
  • the system includes a dry emulsion including lipophilic droplets dispersed within a water soluble polymeric film.
  • the system further includes a solvent for dissolving the film.
  • the solvent is provided for direct contact with the dry emulsion to cause the dry emulsion to be reconstituted, whereby the reconstituted emulsion can be applied to a surface area in need thereof.
  • the system may further include an applicator for applying the
  • a further aspect of the present invention relates to compositions useful for delivering a dispersion of a eutectic composition.
  • the invention provides a composition including a solid water soluble polymeric matrix; and a plurality of droplets of a eutectic composition dispersed within the matrix, the composition forming a dispersion of the eutectic composition when exposed to water.
  • Figure 1 shows a side view of a package containing a unit dosage film of the present invention.
  • Figure 2 shows a top view of two adjacently coupled packages containing individual unit dosage forms of the present invention, separated by a tearable perforation.
  • Figure 3 shows a side view of the adjacently coupled packages of Figure 2 arranged in a stacked configuration.
  • Figure 4 shows a perspective view of a dispenser for dispensing the packaged unit dosage forms, dispenser containing the packaged unit dosage forms in a stacked
  • Figure 5 is a schematic view of a roll of coupled unit dose packages of the present invention.
  • Figure 6 is a schematic view of an apparatus suitable for preparation of a pre-mix, addition of an active, and subsequent formation of the film.
  • Figure 7 is a schematic view of an apparatus suitable for drying the films of the present invention.
  • Figure 8 is a sequential representation of the drying process of the present invention.
  • Figure 9 is a schematic representation of a continuously-linked zone drying apparatus in accordance with the present invention.
  • Figure 10 is a schematic representation of a separate zone drying apparatus in accordance with the present invention.
  • non-self-aggregating uniform heterogeneity refers to the ability of the films of the present invention, which are formed from one or more components in addition to a polar solvent, to provide a substantially reduced occurrence of, i.e. little or no, aggregation or conglomeration of components within the film as is normally experienced when films are formed by conventional drying methods such as a high-temperature air-bath using a drying oven, drying tunnel, vacuum drier, or other such drying equipment.
  • heterogeneity as used in the present invention, includes films that will incorporate a single component, such as a polymer, as well as combinations of components, such as a polymer and an active. Uniform heterogeneity includes the substantial absence of aggregates or conglomerates as is common in conventional mixing and heat drying methods used to form films.
  • the films of the present invention have a substantially uniform thickness, which is also not provided by the use of conventional drying methods used for drying water- based polymer systems.
  • the absence of a uniform thickness detrimentally affects uniformity of component distribution throughout the area of a given film.
  • the film products of the present invention are produced by a combination of a properly selected polymer(s), a polar solvent and a topical agent, as well as other fillers known in the art. These films provide a non-self-aggregating uniform heterogeneity of the components within them by utilizing a selected casting or deposition method and a controlled drying process. Examples of controlled drying processes include, but are not limited to, the use of the apparatus disclosed in U.S. Patent No. 4,631,837 to Magoon ("Magoon”), herein incorporated by reference, as well as hot air impingement across the bottom substrate and bottom heating plates.
  • Another drying technique for obtaining the films of the present invention is controlled radiation drying, in the absence of uncontrolled air currents, such as infrared and radio frequency radiation (i.e. microwaves).
  • the objective of the drying process is to provide a method of drying the films that avoids complications, such as the noted "rippling" effect, that are associated with
  • a uniform film is provided by drying the bottom surface of the film first or otherwise preventing the formation of polymer film formation (skin) on the top surface of the film prior to drying the depth of the film. This may be achieved by applying heat to the bottom surface of the film with substantially no top air flow, or alternatively by the introduction of controlled microwaves to evaporate the water or other polar solvent within the film, again with substantially no top air flow.
  • drying may be achieved by using balanced fluid flow, such as balanced air flow, where the bottom and top air flows are controlled to provide a uniform film.
  • the air flow directed at the top of the film should not create a condition which would cause movement of particles present in the wet film, due to forces generated by the air currents.
  • air currents directed at the bottom of the film should desirably be controlled such that the film does not lift up due to forces from the air. Uncontrolled air currents, either above or below the film, can create non-uniformity in the final film products.
  • the humidity level of the area surrounding the top surface may also be appropriately adjusted to prevent premature closure or skinning of the polymer surface.
  • This manner of drying the films provides several advantages. Among these are the faster drying times and a more uniform surface of the film, as well as uniform distribution of components for any given area in the film. In addition, the faster drying time allows viscosity to quickly build within the film, further encouraging a uniform distribution of components and decrease in aggregation of components in the final film product. Desirably, the drying of the film will occur within about ten minutes or fewer, or more desirably within about five minutes or fewer.
  • the present invention yields exceptionally uniform film products when attention is paid to reducing the aggregation of the compositional components.
  • selecting polymers and solvents to provide a controllable viscosity and by drying the film in a rapid manner from the bottom up, such films result.
  • the products and processes of the present invention rely on the interaction among various steps of the production of the films in order to provide films that substantially reduce the self-aggregation of the components within the films.
  • these steps include the particular method used to form the film, making the composition mixture to prevent air bubble inclusions, controlling the viscosity of the film forming composition and the method of drying the film. More particularly, a greater viscosity of components in the mixture is particularly useful when the active is not soluble in the selected polar solvent in order to prevent the active from settling out.
  • the viscosity must not be too great as to hinder or prevent the chosen method of casting, which desirably includes reverse roll coating due to its ability to provide a film of substantially consistent thickness.
  • the present invention In addition to the viscosity of the film or film-forming components or matrix, there are other considerations taken into account by the present invention for achieving desirable film uniformity. For example, stable suspensions are achieved which prevent solid (such as drug particles) sedimentation in non-colloidal applications.
  • One approach provided by the present invention is to balance the density of the particulate (p p ) and the liquid phase (pi) and increase the viscosity of the liquid phase ( ⁇ ).
  • Stokes law relates the terminal settling velocity (Vo) of a rigid spherical body of radius (r) in a viscous fluid, as follows:
  • V o (2gr r )(P p - p0/9 ⁇
  • the local particle concentration will affect the local viscosity and density.
  • the viscosity of the suspension is a strong function of solids volume fraction, and particle-particle and particle-liquid interactions will further hinder settling velocity.
  • Stokian analyses has shown that the incorporation of a third phase, dispersed air or nitrogen, for example, promotes suspension stability. Further, increasing the number of particles leads to a hindered settling effect based on the solids volume fraction, hi dilute particle suspensions, the rate of sedimentation, v, can be expressed as:
  • ⁇ o is the viscosity of the continuous phase and ⁇ is the solids volume fraction.
  • ⁇ is the solids volume fraction.
  • the viscosity of the dispersion can be expressed as
  • ⁇ / ⁇ o 1 + 2.5 ⁇ + C 1 ⁇ 2 + C 2 ⁇ 3 +
  • the viscosity of the liquid phase is critical and is desirably modified by customizing the liquid composition to a viscoelastic non-Newtonian fluid with low yield stress values. This is the equivalent of producing a high viscosity continuous phase at rest. Formation of a viscoelastic or a highly structured fluid phase provides additional resistive forces to particle sedimentation. Further, flocculation or aggregation can be controlled minimizing particle- particle interactions. The net effect would be the preservation of a homogeneous dispersed phase.
  • hydrocolloids to the aqueous phase of the suspension increases viscosity, may produce viscoelasticity and can impart stability depending on the type of hydrocolloid, its concentration and the particle composition, geometry, size, and volume fraction.
  • the particle size distribution of the dispersed phase needs to be controlled by selecting the smallest realistic particle size in the high viscosity medium, i.e., ⁇ 500 ⁇ m.
  • the presence of a slight yield stress or elastic body at low shear rates may also induce permanent stability regardless of the apparent viscosity.
  • the critical particle diameter can be calculated from the yield stress values. In the case of isolated spherical particles, the maximum shear stress developed in settling through a medium of given viscosity can be given as
  • the viscosity in this shear stress regime may well be the zero shear rate viscosity at the Newtonian plateau.
  • a stable suspension is an important characteristic for the manufacture of a pre-mix composition which is to be fed into the film casting machinery film, as well as the maintenance of this stability in the wet film stage until sufficient drying has occurred to lock-in the particles and matrix into a sufficiently solid form such that uniformity is maintained.
  • a rheology that yields stable suspensions for extended time period, such as 24 hours must be balanced with the requirements of highspeed film casting operations.
  • a desirable property for the films is shear thinning or pseudoplasticity, whereby the viscosity decreases with increasing shear rate. Time dependent shear effects such as thixotropy are also advantageous. Structural recovery and shear thinning behavior are important properties, as is the ability for the film to self-level as it is formed. The rheology requirements for the inventive compositions and films are quite severe.
  • rheology is also a defining factor with respect to the ability to form films with the desired uniformity. Shear viscosity, extensional viscosity,
  • ⁇ ( ⁇ "I/n) ⁇ o (n - ⁇ /n) - ((n-l)/(2n-l))( ⁇ /K) 1/n (2 ⁇ / ⁇ ) (3+nyn h (2n+l)/n t
  • ⁇ is the surface wave amplitude
  • ⁇ 0 is the initial amplitude
  • ⁇ is the wavelength of the surface roughness
  • both "n" and "K” are viscosity power law indices.
  • leveling behavior is related to viscosity, increasing as n decreases, and decreasing with increasing K.
  • the films or film-forming compositions of the present invention have a very rapid structural recovery, i.e. as the film is formed during processing, it doesn't fall apart or become discontinuous in its structure and compositional uniformity. Such very rapid structural recovery retards particle settling and sedimentation.
  • the films or film- forming compositions of the present invention are desirably shear-thinning pseudoplastic fluids. Such fluids with consideration of properties, such as viscosity and elasticity, promote thin film formation and uniformity. Thus, uniformity in the mixture of components depends upon numerous variables. As described herein, viscosity of the components, the mixing techniques and the rheological properties of the resultant mixed composition and wet casted film are important aspects of the present invention.
  • the size of the particulate may be a particle size of 150 microns or less, for example 100 microns or less.
  • such particles may be spherical, substantially spherical, or non-spherical, such as irregularly shaped particles or ellipsoidally shaped particles.
  • Ellipsoidally shaped particles or ellipsoids are desirable because of their ability to maintain uniformity in the film forming matrix as they tend to settle to a lesser degree as compared to spherical particles.
  • a number of techniques may be employed in the mixing stage to prevent bubble inclusions in the final film.
  • anti-foaming or surface-tension reducing agents are employed.
  • the speed of the mixture is desirably controlled to prevent cavitation of the mixture in a manner which pulls air into the mix.
  • air bubble reduction can further be achieved by allowing the mix to stand for a sufficient time for bubbles to escape prior to drying the film.
  • the inventive process first forms a masterbatch of film- forming components without active ingredients or volatile materials.
  • the active(s) are combined with smaller mixes of the masterbatch just prior to casting.
  • the masterbatch pre-mix can be allowed to stand for a longer time without concern for instability of the active agent or other ingredients.
  • the material including the film-forming polymer and polar solvent in addition to any additives and the active ingredient, this may be done in a number of steps.
  • the ingredients may all be added together or a pre-mix may be prepared.
  • the advantage of a pre-mix is that all ingredients except for the active may be combined in advance, with the active added just prior to formation of the film. This is especially important for actives that may degrade with prolonged exposure to water, air or another polar solvent.
  • Figure 6 shows an apparatus 20 suitable for the preparation of a pre-mix, addition of an active and subsequent formation of a film.
  • the pre-mix or master batch 22 which includes the film-forming polymer, polar solvent, and any other additives except an active agent is added to the master batch feed tank 24.
  • the components for pre-mix or master batch 22 are desirably formed in a mixer (not shown) prior to their addition into the master batch feed tank 24.
  • a pre-determined amount of the master batch is controllably fed via a first metering pump 26 and control valve 28 to either or both of the first and second mixers, 30, 30'.
  • the present invention is not limited to the use of two mixers, 30, 30', and any number of mixers may suitably be used.
  • the present invention is not limited to any particular sequencing of the mixers 30, 30', such as parallel sequencing as depicted in Figure 6, and other sequencing or arrangements of mixers, such as series or combination of parallel and series, may suitably be used.
  • the required amount of the active or other ingredient is added to the desired mixer through an opening, 32, 32', in each of the mixers, 30, 30'.
  • the residence time of the pre-mix or master batch 22 is minimized in the mixers 3?0, 30'. While complete dispersion of the active into the pre-mix or master batch 22 is desirable, excessive residence times may result in leaching or dissolving of the active, especially in the case for a soluble drug active. Thus, the mixers 30, 30' are often smaller, i.e. lower residence times, as compared to the primary mixers (not shown) used in forming the pre-mix or master batch 22.
  • a specific amount of the uniform matrix is then fed to the pan 36 through the second metering pumps, 34, 34'.
  • the metering roller 38 determines the thickness of the film 42 and applies it to the application roller.
  • the film 42 is finally formed on the substrate 44 and carried away via the support roller 46.
  • the wet film is then dried using controlled bottom drying or controlled microwave drying, desirably in the absence of external air currents or heat on the top (exposed) surface of the film 48 as described herein.
  • Controlled bottom drying or controlled microwave drying advantageously allows for vapor release from the film without the disadvantages of the prior art.
  • Conventional convection air drying from the top is not employed because it initiates drying at the top uppermost portion of the film, thereby forming a barrier against fluid flow, such as the evaporative vapors, and thermal flow, such as the thermal energy for drying.
  • Such dried upper portions serve as a barrier to further vapor release as the portions beneath are dried, which results in non-uniform films.
  • top air flow can be used to aid the drying of the films of the present invention, but it must not create a condition that would cause particle movement or a rippling effect in the film, both of which would result in non-uniformity. If top air is employed, it is balanced with the bottom air drying to avoid non-uniformity and prevent film lift-up on the carrier belt. A balance top and bottom air flow may be suitable where the bottom air flow functions as the major source of drying and the top air flow is the minor source of drying. The advantage of some top air flow is to move the exiting vapors away from the film thereby aiding in the overall drying process.
  • any top air flow or top drying must be balanced by a number of factors including, but not limited, to rheological properties of the composition arid mechanical aspects of the processing.
  • Any top fluid flow such as air
  • Any top fluid flow also must not overcome the inherent viscosity of the film-forming composition. In other words, the top air flow cannot break, distort or otherwise physically disturb the surface of the composition.
  • air velocities are desirably below the yield values of the film, i.e., below any force level that can move the liquids in the film-forming compositions. For thin or low viscosity compositions, low air velocity must be used. For thick or high viscosity compositions, higher air velocities may be used.
  • air velocities are desirable low so as to avoid any lifting or other movement of the film formed from the compositions.
  • the films of the present invention may contain particles that are sensitive to temperature, such as volatile ingredients, or drugs, which may have a low degradation temperature.
  • the drying temperature may be decreased while increasing the drying time to adequately dry the uniform films of the present invention.
  • bottom drying also tends to result in a lower internal film temperature as compared to top drying. In bottom drying, the evaporating vapors more readily carry heat away from the film as compared to top drying which lowers the internal film temperature. Such lower internal film temperatures often result in decreased drug degradation and decreased loss of certain volatiles, such as flavors.
  • Degradation is the "decomposition of a compound . . . exhibiting well- defined intermediate products.” The American Heritage Dictionary of the English Language (4 th ed. 2000). Degradation of an active component is typically undesirable as it may cause instability, inactivity, and/or decreased potency of the active component. For instance, if the active component is a drug or bioactive material, this may adversely affect the safety or efficacy of the final pharmaceutical product. Additionally, highly volatile materials will tend to be quickly released from this film upon exposure to conventional drying methods.
  • Degradation of an active component may occur through a variety of processes, such as, hydrolysis, oxidation, and light degradation, depending upon the particular active component. Moreover, temperature has a significant effect on the rate of such reactions. The rate of degradation typically doubles for every 10 0 C increase in temperature. Therefore, it is commonly understood that exposing an active component to high temperatures will initiate and/or accelerate undesirable degradation reactions. Proteins are one category of useful topical, active agents that may degrade, denature, or otherwise become inactive when they are exposed to high temperatures for extended periods of time. Proteins serve a variety of functions in the body such as enzymes, structural elements, hormones and immunoglobulins.
  • proteins include enzymes such as pancreatin, trypsin, pancrelipase, chymotrypsin, hyaluronidase, sutilains, streptokinaw, urokinase, altiplase, papain, bromelainsdiastase, structural elements such as collagen, elastin and albumin, hormones such as thyroliberin, gonadoliberin, adrenocorticottropin,
  • corticotrophin corticotrophin, cosyntropin, sometrem, somatropion, prolactin, thyrotropin, somatostatin, vasopressin, felypressin, lypressin, insulin, glucagons, gastrin, pentagastrin, secretin, cholecystokinin-pancreozymin, and immunomodulators which may include polysaccharides in addition to glycoproteins including cytokines which are useful for the inhibition and prevention of malignant cell growth such as tumor growth.
  • a suitable method for the production of some useful glycoproteins is disclosed in U.S. Patent No. 6,281,337 to Cannon- Carlson, et al., which in incorporated herein in its entirety.
  • Peptides are another category of useful topical, active agents that have the potential to become inactive when exposed to high temperatures for long periods of time. Peptides may be included in skin care products, for example. Temperatures that approach 100 0 C will generally cause degradation of proteins, certain peptides, as well as nucleic acids. For example, some glycoproteins will degrade if exposed to a temperature of 70 0 C for thirty minutes. Proteins from bovine extract are also known to degrade at such low temperatures. DNA also begins to denature at this
  • the films of the present invention may be exposed to high temperatures during the drying process without concern for degradation, loss of activity, or excessive evaporation due to the inventive process for film preparation and forming.
  • the films may be exposed to temperatures that would typically lead to degradation, denaturization, or inactivity of the active component, without causing such problems.
  • the manner of drying may be controlled to prevent deleterious levels of heat from reaching the active component.
  • the flowable mixture is prepared to be uniform in content in accordance with the teachings of the present invention. Uniformity must be maintained as the flowable mass was formed into a film and dried.
  • the films of the present invention have an extremely short heat history, usually only on the order of minutes, so that total temperature exposure is minimized to the extent possible.
  • the films are controllably dried to prevent aggregation and migration of components, as well as preventing heat build up within. Desirably, the films are dried from the bottom. Controlled bottom drying, as described herein, prevents the formation of a polymer film, or skin, on the top surface of the film. As heat is conducted from the film bottom upward, liquid carrier, e.g., water, rises to the film surface.
  • thermal mixing occurs within the film due to bottom heating and absence of surface skinning. Thermal mixing occurs via convection currents in the film. As heat is applied to the bottom of the film, the liquid near the bottom increases in temperature, expands, and becomes less dense. As such, this hotter liquid rises and cooler liquid takes its place. While rising, the hotter liquid mixes with the cooler liquid and shares thermal energy with it, i.e., transfers heat. As the cycle repeats, thermal energy is spread throughout the film.
  • Robust thermal mixing achieved by the controlled drying process of the present invention produces uniform heat diffusion throughout the film. In the absence of such thermal mixing, "hot spots" may develop. Pockets of heat in the film result in the formation of particle aggregates or danger areas within the film and subsequent non-uniformity. The formation of such aggregates or agglomerations is undesirable because it leads to nonuniform films in which the active may be randomly distributed. Such uneven distribution may lead to large differences in the amount of active per film, which is problematic from a safety and efficacy perspective.
  • thermal mixing helps to maintain a lower overall temperature inside the film. Although the film surfaces may be exposed to a temperature above that at which the active component degrades, the film interior may not reach this temperature. Due to this temperature differential, the active does not degrade.
  • the films of the present invention desirably are dried for 10 minutes or less. Drying the films at 80 0 C for 10 minutes produces a temperature differential of about 5°C. This means that after 10 minutes of drying, the temperature of the inside of the film is 5°C less than the outside exposure temperature. In many cases, however, drying times of less than 10 minutes are sufficient, such as 4 to 6 minutes. Drying for 4 minutes may be accompanied by a temperature differential of about 30 0 C, and drying for 6 minutes may be accompanied by a differential of about 25°C. Due to such large temperature differentials, the films may be dried at efficient, high temperatures without causing heat sensitive actives to degrade.
  • Fig. 8 is a sequential representation of the drying process of the present invention.
  • the film may be placed on a conveyor for continued thermal mixing during the drying process.
  • the film 1 preferably is heated from the bottom 10 as it is travels via conveyor (not shown). Heat may be supplied to the film by a heating mechanism, such as, but not limited to, the dryer depicted in Fig. 7.
  • the liquid carrier, or volatile (“V") begins to evaporate, as shown by upward arrow 50.
  • Thermal mixing also initiates as hotter liquid, depicted by arrow 30, rises and cooler liquid, depicted by arrow 40, takes its place.
  • the volatile liquid continues to evaporate 50 and thermal mixing 30/40 continues to distribute thermal energy throughout the film. Once a sufficient amount of the volatile liquid has evaporated, thermal mixing has produced uniform heat diffusion throughout the film 1.
  • the resulting dried film 1 is a visco- elastic solid, as depicted in Section C.
  • the components desirably are locked into a uniform distribution throughout the film.
  • minor amounts of liquid carrier, i.e., water may remain subsequent to formation of the visco-elastic, the film may be dried further without movement of the particles, if desired.
  • particles or particulates maybe added to the film-forming composition or material after the composition or material is cast into a film.
  • particles may be added to the film 42 prior to the drying of the film 42.
  • Particles may be controllably metered to the film and disposed onto the film through a suitable technique, such as through the use of a doctor blade (not shown), which is a device which marginally or softly touches the surface of the film and controllably disposes the particles onto the film surface.
  • a doctor blade not shown
  • Other suitable, but non-limiting, techniques include the use of an additional roller to place the particles on the film surface, spraying the particles onto the film surface, and the like.
  • the particles may be placed on either or both of the opposed film surfaces, i.e., the top and/or bottom film surfaces.
  • the particles are securably disposed onto the film, such as being embedded into the film.
  • such particles are desirably not fully encased or fully embedded into the film, but remain exposed to the surface of the film, such as in the case where the particles are partially embedded or partially encased.
  • the particles may be any useful topical agents(s).
  • Useful topical agents include personal . care products and medicinal agents.
  • the topical agent may be selected from the following: soaps, body washing agents, hair shampoos, hair conditioners, hair styling agents, moisturizing agents, underarm deodorants and/or antiperspirants, shaving creams or gels, sunscreens and insect repellants.
  • the topical agent may be selected from antibacterial agents, acne medications, hormones, agents for preventing motion sickness and anesthetics, such as prilocaine, lidocaine and combinations thereof.
  • Drying apparatus 50 is a nozzle arrangement for directing hot fluid, such as but not limited to hot air, towards the bottom of the film 42 which is disposed on substrate 44.
  • Hot air enters the entrance end 52 of the drying apparatus and travels vertically upward, as depicted by vectors 54, towards air deflector 56.
  • the air deflector 56 redirects the air movement to minimize upward force on the film 42.
  • the air is tangentially directed, as indicated by vectors 60 and 60', as the air passes by air deflector 56 and enters and travels through chamber portions 58 and 58' of the drying apparatus 50.
  • the hot air flow being substantially tangential to the film 42, lifting of the; film as it is being dried is thereby minimized.
  • the air deflector 56 is depicted as a roller, other devices and geometries for deflecting air or hot fluid may suitable be used.
  • the exit ends 62 and 62' of the drying apparatus 50 are flared downwardly. Such downward flaring provides a downward force or downward velocity vector, as indicated by vectors 64 and 64', which tend to provide a pulling or drag effect of the film 42 to prevent lifting of the film 42. Lifting of the film 42 may not only result in non-uniformity in the film or otherwise, but may also result in non-controlled processing of the film 42 as the film 42 and/or substrate 44 lift away from the processing equipment.
  • the thickness of the film may be monitored with gauges such as Beta Gauges.
  • a gauge may be coupled to another gauge at the end of the drying apparatus, i.e. drying oven.or tunnel, to communicate through feedback loops to control and adjust the opening in the coating apparatus, resulting in control of uniform film thickness.
  • the film products are generally formed by combining a properly selected polymer and polar solvent, as well as any topical agent or filler as desired. Desirably, sthe solvent content of the combination is at least about 30% by weight of the total combination.
  • the material formed by this combination is formed into a film, desirably by roll coating, and then dried, desirably by a rapid and controlled drying process to maintain the uniformity of the film, more specifically, a non- self-aggregating uniform heterogeneity.
  • the resulting film will desirably contain less than about 10% by weight solvent, more desirably less than about 8% by weight solvent, even more desirably less than about 6% by weight solvent and most desirably less than about 2%.
  • the solvent may be water, a polar organic solvent including, but not limited to, ethanol, isopropanol, acetone, methylene chloride, or any combination thereof.
  • compositions of the present invention including a pharmaceutical and/or cosmetic dosage form or film product having no more than a 10% variance of a pharmaceutical and/or cosmetic active per unit area.
  • uniformity of the present invention is determined by the presence of no more than a 10% by weight of pharmaceutical and/or cosmetic variance throughout the matrix.
  • the variance is less than 5% by weight, less than 2% by weight, less than 1% by weight, or less than 0.5% by weight.
  • the film units of the present invention include at least one water soluble polymer.
  • the films may also include water swellable or water insoluble polymers, if desired.
  • the self-supporting film includes a saccharide-based polymer, which is water soluble.
  • the saccharide-based polymer may be cellulose or a cellulose derivative.
  • Specific examples of useful saccharide-based, water soluble polymers include, but are not limited to, polydextrose, pullulan, hydroxypropylmethyl cellulose (HPMC), hydroxyethyl cellulose (HPC), hydroxypropyl cellulose, carboxymethyl cellulose, sodium aginate, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, starch, gelatin, and combinations thereof.
  • the saccharide-based polymer may be at least one cellulosic polymer, polydextrose, or combinations thereof.
  • the film may also include non- saccharide-based. water soluble or water insoluble polymers.
  • non-saccharide based, water soluble polymers include polyethylene oxide, polyvinylpyrrolidone, polyvinyl- alcohol, polyethylene glycol, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, and combinations thereof.
  • Specific examples of useful water insoluble polymers include, but are not limited to, ethyl cellulose, hydroxypropyl ethyl cellulose, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate and combinations thereof.
  • the polymer is a combination of
  • the polymer is a combination of polydextrose and polyethylene oxide. In still further preferred embodiments, the polymer is a combination of polydextrose, hydroxy propylmethyl cellulose and polyethylene oxide.
  • water soluble polymer and variants thereof refer to a polymer that is at least partially soluble in water, and desirably fully or predominantly soluble in water, or absorbs water.
  • the film unit of the present invention is at least partially dissolvable when exposed to a wetting agent. In some other embodiments, the inventive film unit is substantially dissolvable when exposed to a wetting agent.
  • Polymers that absorb water are often referred to as being water swellable polymers.
  • the materials useful with the present invention may be water soluble or water swellable at room temperature and other temperatures, such as temperatures exceeding room temperature. Moreover, the materials may be water soluble or water swellable at pressures less than atmospheric pressure. Desirably, the water soluble polymers are water soluble or water swellable having at least 20 percent by weight water uptake. Water swellable polymers having a 25 or greater percent by weight water uptake are also useful. Films or dosage forms of the present invention formed from such water soluble polymers are desirably sufficiently water soluble to be dissolvable upon contact with bodily fluids.
  • polymers useful for incorporation into the films of the present invention include biodegradable polymers, copolymers, block polymers and combinations thereof.
  • biodegradable polymers include biodegradable polymers, copolymers, block polymers and combinations thereof.
  • known useful polymers or polymer classes which meet the above criteria are: poly(glycolic acid) (PGA), poly(lactic acid) (PLA), polydioxanoes, polyoxalates, poly( ⁇ -esters), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acids, polyaminocarbonates, polyurethanes, polycarbonates, polyamides, poly(alkyl)
  • Additional useful polymers include, stereopolymers of L- and D-lactic acid, copolymers of bis(p-carboxyphenoxy) propane acid and sebacic acid, sebacic acid copolymers, copolymers of caprolactone, poly(lactic acid)/poly(glycolic acid)/ ⁇ olyethyleneglycol copolymers, copolymers of polyurethane and (poly(lactic acid), copolymers of polyurethane and poly(lactic acid), copolymers of ⁇ -amino acids, copolymers of ⁇ -amino acids and caproic acid, copolymers of ⁇ -benzyl glutamate and polyethylene glycol, copolymers of succinate and poly(glycols), polyphosphazene, polyhydroxy-alkanoates and mixtures thereof. Binary and ternary systems are contemplated.
  • lactide/glycolide 85/15 believed to be 85% lactide and 15% glycolide with a melting point within the range of 338°-347°F (170°-175° C); and lactide/glycolide 50/50, believed to be a copolymer of 50% lactide and 50% glycolide with a melting point within the range of 338°- 347 o F (170°-175°C).
  • Biodel materials represent a family of various polyanhydrides which differ chemically.
  • polymers may be used, it is desired to select polymers to provide a desired viscosity of the mixture prior to drying. For example, if the topical agent or other components are not soluble in the selected solvent, a polymer that will provide a greater viscosity is desired to assist in maintaining uniformity. On the other hand, if the components are soluble in the solvent, a polymer that provides a lower viscosity may be preferred.
  • Viscosity is one property of a liquid that controls the stability of the topical agent in an emulsion, a colloid or a suspension.
  • the viscosity of the matrix will vary from about 400 cps to about 100,000 cps, preferably from about 800 cps to about 60,000 cps, and most preferably from about 1,000 cps to about 40,000 cps. Desirably, the viscosity of the film-forming matrix will rapidly increase upon initiation of the drying process.
  • the viscosity may be adjusted based on the selected topical agent component, depending on the other components within the matrix. For example, if the component is not soluble within the selected solvent, a proper viscosity may be selected to prevent the component from settling which would adversely affect the uniformity of the resulting film.
  • the viscosity may be adjusted in different ways.
  • the polymer may be chosen of a higher molecular weight or crosslinkers may be added, such as salts of calcium, sodium and potassium.
  • the viscosity may also be adjusted by adjusting the temperature or by adding a viscosity increasing component.
  • Components that will increase the viscosity or stabilize the emulsion/suspension include higher molecular weight polymers and polysaccharides and gums, which include without limitation, alginate, carrageenan, hydroxypropyl methyl cellulose, locust bean gum, guar gum, xanthan gum, dextran, gum arabic, gellan gum and combinations thereof.
  • HPMC and HPC when used in combination provide a flexible, strong film with the appropriate plasticity and elasticity for manufacturing and storage. No additional plasticizer or polyalcohol is needed for flexibility.
  • polyethylene oxide when used alone or in combination with a hydrophilic cellulosic polymer and/or polydextrose, achieves flexible, strong films.
  • Non-limiting examples of suitable cellulosic polymers for combination with PEO include HPC and HPMC.
  • PEO and HPC have essentially no gelation temperature, while HPMC has a gelation temperature of 58- 64°C (Methocel EF available from Dow Chemical Co.).
  • these films are sufficiently flexible even when substantially free of organic solvents, which maybe removed without compromising film properties. As such, if there is no solvent present, then there is no plasticizer in the films.
  • PEO based films also exhibit good resistance to tearing, little or no curling, and fast dissolution rates when the polymer component contains appropriate levels of PEO.
  • the level and/or molecular weight of PEO in the polymer component may be varied. Modifying the PEO content affects properties such as tear resistance, dissolution rate, and adhesion tendencies. Thus, one method for controlling film properties is to modify the PEO content. For instance, in some embodiments rapid dissolving films are desirable. By modifying the content of the polymer component, the desired dissolution characteristics can be achieved.
  • PEO desirably ranges from about 20% to 100% by weight in the polymer component. In some embodiments, the amount of PEO desirably ranges from about lmg to about 200mg.
  • the hydrophilic cellulosic polymer and/or polydextrose ranges from about 0% to about 80% by weight, or in a ratio of up to about 4:1 with the PEO, and desirably in a ratio of about 1:1. .
  • PEO levels it may be desirable to vary the PEO levels to promote certain film properties.
  • levels of about 50% or greater of PEO in the polymer component are desirable.
  • adhesion prevention i.e., preventing the film from adhering to the roof of the mouth
  • PEO levels of about 20% to 75% are desirable.
  • adhesion to the roof of the mouth may be desired, such as for administration to animals or children. In such cases, higher levels of PEO may be employed. More specifically, structural integrity and
  • the molecular weight of the PEO may also be varied.
  • High molecular weight PEO such as about 4 million, may be desired to increase mucoadhesivity of the film. More desirably, the molecular weight may range from about 100,000 to 900,000, more desirably from about 100,000 to 600,000, and most desirably from about 100,000 to 300,000. In some embodiments, it may be desirable to combine high molecular weight (600,000 to 900,000) with low molecular weight (100,000 to 300,000) PEOs in the polymer component.
  • certain film properties such as fast dissolution rates and high tear resistance, may be attained by combining small amounts of high molecular weight PEOs with larger amounts of lower molecular weight PEOs.
  • such compositions contain about 60% or greater levels of the lower molecular weight PEO in the PEO-blend polymer component.
  • desirable film compositions may include about 50% to 75% low molecular weight PEO, optionally combined with a small amount of a higher molecular weight PEO, with the remainder of the polymer component containing a hydrophilic cellulosic polymer (HPC or HPMC) and/or polydextrose.
  • HPC hydrophilic cellulosic polymer
  • controlled release is intended to mean the release of the topical agent at a pre-selected or desired rate.
  • the topical agent is a medicament
  • the polymers that are chosen for the films of the present invention may also be chosen to allow for controlled disintegration of the topical agent. This may be achieved by providing a substantially water insoluble film that incorporates a topical agent that will be released from the film over time. This may be accomplished by incorporating a variety of different soluble or insoluble polymers and may also include biodegradable polymers in combination. Alternatively, coated controlled release topical agent particles may be incorporated into a readily soluble film matrix to achieve the controlled release property of the agent.
  • the topical agents employed in the present invention may be incorporated into the film compositions of the present invention in a controlled release form.
  • particles of a drug may be coated with polymers, such as ethyl cellulose or polymethacrylate, which are commercially available under brand names such as Aquacoat ECD and Eudragit E- 100, respectively. Solutions of a drug may also be absorbed on such polymer materials and incorporated into the inventive film compositions. Other components may also be employed in such controlled release compositions.
  • the amount of topical agent per unit area is determined by the uniform distribution of the film. For example, when the films are cut into individual units, the amount of the topical agent in the unit can be known with a great deal of accuracy. This is achieved because the amount of the topical agent in a given area is substantially identical to the amount of topical agent in an area of the same dimensions in another part of the film.
  • the accuracy in dosage is particularly advantageous when the topical agent is a medicament, i.e. a drug.
  • the topical agents that may be incorporated into the films of the present invention include, but are not limited to, pharmaceutical, cosmetic, cosmeceutical and nutraceutical actives.
  • a cosmeceutical refers to a product, which is a cosmetic, but which contains biologically active ingredients that have an effect on the user.
  • a nutraceutical refers to a product isolated or purified from foods, and sold in medicinal forms not usually associated with food and demonstrated to have a physiological benefit or provide protection against disease. Examples of nutraceuticals include beta-carotene and lycopene.
  • a topical agent pertains to an agent that may be applied to a particular surface area, such as, but not limited to, a certain area of the skin or mucosal tissue.
  • the film is used as a delivery system to carry the topical ingredient to a particular surface area in need thereof.
  • the polymeric film desirably includes at least one water soluble polymer. In some other embodiments, the film includes a combination of both water soluble and water insoluble polymers.
  • the dry film product When wetted, the dry film product at least partially solubilizes.
  • a wetting agent permits the topical agent to be dissolved or dispersed out of the film.
  • the wetting agent may be a polar solvent, such as water.
  • the dissolved or dispersed topical agent may then be easily applied to a particular surface area, such as a skin area.
  • the wetting agent may be placed on a substrate surface, including skin and wounds, and the film placed on the wetted surface. Alternatively, the film may be placed on the substrate surface, including skin and wounds, and subsequently hydrated.
  • the wetting agent may be dispensed from a container, the container being separate from or affixed to the film.
  • the container may be a pump bottle or sealed tube
  • the container may be a sealed, rupturable pouch including the wetting agent.
  • a pouch may be separate from or affixed to the firm.
  • the wetting agent may be brought into direct contact with the film to cause the topical agent to be dissolved out or dispersed out of the film, whereby the topical agent can be applied to the substrate surface.
  • the film may be interposed between a container including the solvent and a substrate surface, including skin and wounds.
  • the film may be interposed between a container including the solvent and an applicator.
  • a system useful for applying a topical agent includes a water soluble polymeric film containing the topical agent, a solvent, which may be present in a container, and an applicator for applying the topical agent to the substrate surface.
  • the applicator is a sponge applicator.
  • the film may be deposited on top of a wetted sponge applicator.
  • the firm may be deposited on top of a dry sponge applicator, which is subsequently wetted.
  • the method of making the films of the present invention involves combining a water soluble, saccharide-based polymer, a polar solvent and the topical agent to form a wet material or matrix with a non-self-aggregating uniform heterogeneity.
  • a blend of water soluble polymers is used, such as at least one saccharide-based polymer and polyethylene oxide.
  • the wet material or matrix is then formed into a film and dried in a controlled manner.
  • the topical agent when combined with the polymer and the polar solvent, is in the form of a liquid, a solid or a gel.
  • the type of material that is formed depends on the solubilities of the topical agent and the polymer(s). If the agent and/or polymer(s) are soluble in the selected solvent, this may form a solution. However, if the components are not soluble, the material that is formed may be classified as an emulsion, a colloid, or a suspension.
  • the topical agent is a personal care agent.
  • the topical agent may also be a medicinal agent.
  • suitable topical agents which may be included in the films of the present invention include, but are not limited to, soaps, body washing agents, hair shampoos, hair conditioners, hair styling agents, moisturizing agents, underarm deodorants and/or antiperspirants, shaving creams or gels, sunscreens, and insect repellants.
  • the topical agent may also be a protein and/or peptide.
  • the topical agent may be collagen, elastin or a combination thereof.
  • these include, but are not limited to, acne medications, antibacterial agents (e.g., antibiotics), hormones, agents for preventing motion sickness, and anesthetics.
  • a medicinal agent in a nanoparticle size such as less than about 500nm, may be combined with a water-soluble polymer composition to form a self- supporting film in accordance with the present invention.
  • a medicinal agent in a nanoparticle size such as preferably less than about 200nm, may be combined with a water-soluble polymer composition to form a self-supporting film in accordance with the present invention.
  • a wide variety of medicaments, bioactive active substances and pharmaceutical compositions may be included in the dosage forms of the present invention.
  • useful drugs include ace-inhibitors, antianginal drugs, anti- arrhythmias, anti-asthmatics, anti- cholesterolemics, analgesics, anesthetics, anti-convulsants, anti-depressants, anti-diabetic agents, anti-diarrhea preparations, antidotes, anti-histamines, anti-hypertensive drugs, antiinflammatory agents, anti-lipid agents, anti-manics, anti-nauseants, anti-stroke agents, anti- thyroid preparations, anti-tumor drugs, anti-viral agents, acne drugs, alkaloids, amino acid preparations, anti-tussives, anti-uricemic drugs, anti-viral drugs, anabolic, preparations, systemic and non-systemic anti-infective agents, anti-neoplasties, antiparkinsonian agents, anti-rheumatic agents
  • prostaglandins psychotherapeutic agents, respiratory agents, sedatives, smoking cessation aids, sympatholytics, tremor preparations, urinary tract agents, vasodilators, laxatives, antacids, ion exchange resins, anti-pyretics, appetite suppressants, expectorants, anti-anxiety agents, anti-ulcer agents, anti-inflammatory substances, coronary dilators, cerebral dilators, peripheral vasodilators, psycho-tropics, stimulants, anti-hypertensive drugs, vasoconstrictors, migraine treatments, antibiotics, tranquilizers, anti-psychotics, anti-tumor drugs, anticoagulants, anti-thrombotic drugs, hypnotics, anti-emetics, anti-nauseants, anti-convulsants, neuromuscular drugs, hyper- and hypo-glycemic agents, thyroid and anti4hyroid
  • medicating active ingredients contemplated for use in the present invention include antacids, H2-antagonists, and analgesics.
  • antacid dosages can be prepared using the ingredients calcium carbonate alone or in combination with magnesium hydroxide, and/or aluminum hydroxide.
  • antacids can be used in combination with H 2 -antagonists.
  • Analgesics include opiates and opiate derivatives, such as oxycodone (available as Oxycontin®), ibuprofen, aspirin, acetaminophen, and combinations thereof that may optionally include caffeine.
  • Opiate agonists, and antagonists, such as bupermorphine and naloxone are further examples of drugs for use in the present invention.
  • anti-diarrheals such as immodium AD, anti-histamines, anti-tussives, decongestants, vitamins, and breath fresheners.
  • anxiolytics such as alprazolam (available as
  • Xanax® anti-psychotics such as clozopin (available as Clozaril®) and haloperidol
  • non-steroidal antiinflammatories such as dicyclofenacs (available as Voltaren®) and etodolac (available as Lodine®), anti-histamines such as diphenhydramine HCl (available as Benadryl®), such as loratadine (available as Claritin®), astemizole (available as HismanalTM), nabumetone (available as Relafen®), diphenydramine HCL (available as TheraFlu®) and Clemastine (available as Tavist®); anti-emetics such as granisetron hydrochloride (available as Kytril®) and nabilone (available as CesametTM); bronchodilators such as Bentolin®, albuterol sulfate (available as Proventil®); antidepressants such as fluoxetine hydrochloride (available as Prozac®), sertraline hydrochloride (available as Zoloft®
  • sedative/hypnotics such as zaleplon (available as Sonata®) and eszopiclone (available as Lunesta®).
  • Erectile dysfunction therapies include, but are not limited to, drugs for facilitating blood flow to the penis, and for effecting autonomic nervous activities, such as increasing parasympathetic (cholinergic) and decreasing sympathetic (adrenersic) activities.
  • useful non-limiting drugs include sildenafils, such as Viagra®, tadalafils, such as Cialis®, vardenafils, apomorphines, such as Uprima®, yohimbine hydrochlorides such as
  • Aphrodyne®, and alprostadils such as Caverject®.
  • H 2 -antagonists which are contemplated for use in the present invention include cimetidine, ranitidine hydrochloride, famotidine, nizatidien, ebrotidine, mifentidine, roxatidine, pisatidine and aceroxatidine.
  • Active antacid ingredients include, but are not limited to, the following: aluminum hydroxide, dihydroxyaluminum aminoacetate, aminoacetic acid, aluminum phosphate, dihydroxyaluminum sodium carbonate, bicarbonate, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, bismuth subsilysilate, calcium carbonate, calcium phosphate, citrate ion (acid or salt), amino acetic acid, hydrate magnesium aluminate sulfate, magaldrate, magnesium aluminosilicate, magnesium carbonate,
  • magnesium glycinate magnesium hydroxide, magnesium oxide, magnesium trisilicate, milk solids, aluminum mono-ordibasic calcium phosphate, tricalcium phosphate, potassium bicarbonate, sodium tartrate, sodium bicarbonate, magnesium aluminosilicates, tartaric acids and salts.
  • the pharmaceutically active agents employed in the present invention may include allergens or antigens, such as, but not limited to, plant pollens from grasses, trees, or ragweed; animal danders, which are tiny scales shed from the skin and hair of cats and other furred animals; insects, such as house dust mites, bees, and wasps; and drugs, such as penicillin.
  • allergens or antigens such as, but not limited to, plant pollens from grasses, trees, or ragweed
  • animal danders which are tiny scales shed from the skin and hair of cats and other furred animals
  • insects such as house dust mites, bees, and wasps
  • drugs such as penicillin.
  • Color additives can be used in preparing the films. Such color additives include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C). These colors are dyes, their corresponding lakes, and certain natural and derived colorants. Lakes are dyes absorbed on aluminum hydroxide. Other examples of coloring agents include known azo dyes, organic or inorganic pigments, or coloring agents of natural origin. Inorganic pigments are preferred, such as the oxides or iron or titanium, these oxides, being added in concentrations ranging from about 0.001 to about 10%, and preferably about 0.5 to about 3%, based on the weight of all the components.
  • fragrances can be included in the films. These may include extracts derived from plants, leaves, flowers, fruits and combinations thereof, for example.
  • topical agent may be any agent that can be applied to a particular surface area.
  • a topical agent may be a cleaning agent that can be applied to substrate in need of cleaning.
  • the topical agent is dish detergent, which may be incorporated into the film, and dried. When wetted, the dish detergent is dispersed out of the film and can be used to clean dishes or other surfaces.
  • topical agents may be classified as emulsion
  • An emulsion is typically a fluid consisting of a heterogeneous mixture of two normally immiscible liquid phases, in which one liquid forms droplets suspended in the other liquid.
  • Emulsion compositions may include, but are not limited to, skin care creams, sunscreens, insect repellants, hair conditioners, hair styling agents (e.g., hair thickening agents), certain shampoos, and pharmaceutical ointments. Such products are traditionally sold as liquids or semi-solids (e.g., ointments).
  • liquid/liquid emulsions may be captured in a flowable film matrix, which when dried transforms the liquid/liquid emulsion into a liqiuid/solid emulsion. At least a portion of the water from the captured emulsion may be evaporated during the drying of the film.
  • the resultant dried film product may be a solid film matrix having a plurality of discrete lipophilic droplets dispersed therein, the droplets being deposited from the liquid/liquid emulsion.
  • the dried film is readily rehydrated to dissolve the water soluble matrix and reform the emulsion by contacting the film with water.
  • lipophilic means having an affinity or attraction for lipids.
  • the lipophilic droplets captured within the film during drying of the film may include therewithin drugs.
  • a drug emulsion is formed, which may be topically applied.
  • a method of preparing an emulsion composition in accordance with the present invention includes providing an aqueous-based emulsion; and converting the aqueous-based emulsion into a non-aqueous dry emulsion, wherein the dry emulsion is in the form of a self-supporting film. The method further includes dissolving the film with an aqueous solvent, thereby reforming the aqueous-based emulsion.
  • the invention provides a product which readily forms an emulsion upon contact with water, with very low energy input. Since the lipophilic droplets are already formed and suspended in the water soluble matrix, once the matrix is solubilized by contact with water, the liquid droplets readily become suspended in the surrounding water.
  • the lipophilic droplets are preferably microscopically discrete and distinct droplets that have an affinity for lipids.
  • the lipophilic droplets may be fat droplets, oil droplets, wax droplets, sterol droplets, glyceride droplets, or combinations thereof.
  • a film of the present invention may be formed by preparing a composition including at least one water soluble polymer, a polar solvent (e.g., water), and an emulsion
  • the emulsion composition employed to prepare the film may include an active, such that, during the drying process, a plurality of lipophilic droplets including the active become dispersed in the film.
  • the emulsion in effect, remains stable and intact during drying, and can be reconsituted when water is added back to dissolve the film. The reconsituted emulsion may then be applied topically.
  • the films of the present invention are particularly well suited for delivery of small drug particles, such as nanoparticles.
  • Nanoparticles are generally understood to be particles which have an average size of less than one micron. Typically this is an average diameter size.
  • the emulsions of the present invention include the drug particles, for example nanoparticles, to be captured within the lipophilic droplets which themselves are captured within the film and which when reconstituted with appropriate solvent, such as aqueous media, can be released.
  • the presence of the active need not be limited, however, to the lipophilic droplets but can also be included in the matrix of the film. Additionally, one or more actives can be present and different actives may be included in a lipophilic droplet and concurrently in the film matrix.
  • liquid crystal structures such those used in U.S.
  • Patent 5,891,845 which is herein incorporated in its entirety by reference, may be employed to deliver and/or control the release of drugs.
  • These liquid crystal structures may be included in the films.
  • Liquid crystal structures may include solid solutions of the drug and film. While not wishing to be bound by any one theory, it is believed that, in the present invention, the film rheology changes so quickly during drying that the emulsion, which typically will break when heated and water is evaporated, is in fact still intact. The emulsion characteristics are substantially maintained, even when all of the water is evaporated away during the film drying process. When water is added back to the film, the emulsion reforms, and can be delivered topically or orally.
  • the drying process includes heating the film at a temperature above the phase inversion temperature of the emulsion composition.
  • a phase inversion temperature for an emulsion is the temperature at which an emulsion will go from either a water/oil emulsion to an oil/water emulsion or vice versa.
  • one phase i.e., oil
  • the oil droplets are captured in the film before coalescence of the oil droplets can occur, thereby permitting the system to be stabilized at a higher energy state relative to that if the emulsion converted to just one phase in the absence of water.
  • the film is heated at a temperature above the phase inversion temperature for the emulsion in order to capture a plurality of oil droplets in the film.
  • the drying is performed for about 10 to about 15 minutes.
  • an emulsion may be prepared by providing a solid water soluble polymeric film having dispersed therein a plurality of the lipophilic droplets; and adding water to dissolve the film, thereby forming an emulsion.
  • the emulsion may be applied to surface in need thereof, such as a body surface.
  • a further aspect of the present invention relates to a method of preparing a water reconsitutable emulsion composition.
  • the method includes preparing a composition including at least one water soluble polymer; a polar solvent; and an emulsion composition.
  • the method further includes drying the composition to form a dry emulsion including lipophilic droplets dispersed within a solid water soluble polymeric matrix.
  • the drying process may include heating at a temperature above the critical inversion temperature of the emulsion.
  • the dry emulsion is formed by drying for about 10 to about 15 minutes.
  • a system useful for applying an emulsion includes a dry emulsion including lipophilic droplets dispersed with a water soluble polymeric film; and a solvent for dissolving the polymeric film.
  • the solvent is provided for direct contact with the dry emulsion to cause the dry emulsion to be reconstituted, whereby the reconstituted emulsion can be applied to the substrate surface, including skin and wounds.
  • the solvent may be present in a container separate from or affixed to the film.
  • Stiitable containers include, but are not limited to, pump bottles, sealed tubes and sealed, rupturable pouches.
  • the system may optionally include an applicator for applying the reconstituted emulsion to the substrate surface.
  • the applicator may, for example, be a sponge.
  • the film is deposited on top of a wetted sponge applicator. In some other embodiments, the film is deposited on top of a dry sponge applicator, which when
  • the film may be interposed between a container including the solvent and an area of skin.
  • the film may be interposed between a container including the solvent and an applicator, such as a sponge applicator.
  • the films of the present invention are useful for delivering a pharmaceutical, cosmetic, cosmeceutical or nutraceutical active.
  • the lipophilic droplets deposited from a liquid/liquid emulsion may contain any of the actives described herein, such as drugs, vitamins, minerals, medicinal agents, herbals, botanicals, animal extracts or products, cosmetic ingredients, cosmeceuticals or nutraceuticals.
  • the active is solubilized in the lipophilic droplets.
  • the active is suspended in the lipophilic droplets.
  • the present invention also provides film compositions, which are useful for delivering a dispersion of a eutectic composition.
  • the film composition includes a solid water soluble polymeric matrix; and a plurality of droplets of a eutectic composition dispersed within the matrix.
  • the film composition forms a dispersion of the eutectic composition when exposed to water.
  • a eutectic composition is a mixture of two or more components which has a lower melting point than any of its constituents.
  • the eutectic composition is a mixture of prilocaine and lidocaine.
  • a eutectic composition can be formed in situ from lidocaine and the HCl salt of prilocaine, as shown in the examples below.
  • the HCl salt of prilocaine was neutralized with sodium hydroxide in situ in order to obtain the prilocaine base needed to form the eutectic composition with lidocaine.
  • prilocaine/lidocaine eutectic was combined with a blend of polymers in the presence of water to produce a film containing a dispersion of the eutectic oil as observed under a microscope. When wetted, the film dissolved, and turned opaque, indicating that the eutectic oil was being released as small emulsion-type droplets.
  • the film products of the present invention are capable of accommodating a wide range of amounts of the topical agent.
  • the films are capable of providing an accurate dosage amount (determined by the size of the film and concentration of the topical agent in the original polymer/water combination) regardless of whether the required dosage is high or extremely low. Therefore, depending on the type of topical agent that is incorporated into the film, the topical agent amount may be as high as about 300mg, desirably up to about 150mg or as low as the microgram range, or any amount therebetween.
  • the film products and methods of the present invention are well suited for high potency, low dosage topical drugs. This is accomplished through the high degree of uniformity of the films. Therefore, low dosage drugs, particularly more potent racemic mixtures of actives are desirable.
  • Anti-foaming and/or de-foaming components may also be used with the films of the present invention. These components aid in the removal of air, such as entrapped air, from the film-forming compositions. As described above, such entrapped air may lead to non- 10 uniform films. Simethicone is one particularly useful anti-foaming and/or de-foaming agent.
  • the present invention is not so limited and other anti-foam and/or de-foaming agents may suitable be used.
  • Simethicone is generally used in the medical field as a treatment for gas or colic in 15 babies.
  • Simethicone is a mixture of fully methylated linear siloxane polymers containing repeating units of polydimethylsiloxane which is stabilized with trimethylsiloxy end-blocking unites, and silicon dioxide. It usually contains 90.5-99% polymethylsiloxane and 4-7% silicon dioxide. The mixture is a gray, translucent, viscous fluid which is insoluble in water.
  • simethicone When dispersed in water, simethicone will spread across the surface, forming a thin film of low surface tension. In this way, simethicone reduces the surface tension of bubbles air located in the solution, such as foam bubbles, causing their collapse.
  • the function of simethicone mimics the dual action of oil and alcohol in water. For example, in an oily solution any trapped air bubbles will ascend to the surface and dissipate more quickly and
  • simethicone has an excellent anti-foaming property that can be used for physiological processes (anti-gas in stomach) as well as any for external processes that require the removal of air bubbles from a product.
  • the mixing step can be performed under vacuum. However, as soon as the mixing step is completed, and the film solution is returned to the normal atmosphere condition, air will be re-introduced into or contacted with the mixture. In many cases, tiny air bubbles will be again trapped inside this polymeric viscous solution.
  • the incorporation of simethicone into the film-forming composition either substantially reduces or eliminates the formation of air bubbles.
  • Simethicone may be added to the fihii-forming mixture as an anti-foaming agent in an amount from.about 0.01 weight percent to about 5.0 weight percent, more desirably from about 0. 05 weight percent to about 2.5 weight percent, and most desirably from about 0. 1 weight percent to about 1.0 weight percent.
  • a variety of other components and fillers may also be added to the films of the present invention. These may include, without limitation, surfactants; plasticizers which assist in compatibilizing the components within the mixture; polyalcohols; anti-foaming agents, such as silicone-containing compounds, which promote a smoother film surface by releasing oxygen from the film; and thermo-setting gels such as pectin, carageenan, and gelatin, which help in maintaining the dispersion of components.
  • additives that can be incorporated into the inventive compositions may provide a variety of different functions.
  • classes of additives include excipients, lubricants, buffering agents, stabilizers, blowing agents, pigments, coloring agents, fillers, bulking agents, fragrances, release modifiers, adjuvants, plasticizers, flow accelerators, mold release agents, polyols, granulating agents, diluents, binders, buffers, absorbents, glidants, adhesives, anti-adherents, acidulants, softeners, resins, demulcents, solvents, surfactants, emulsifiers, elastomers and mixtures thereof. These additives may be added with the active ingredient(s).
  • Useful additives include, for example, gelatin, vegetable proteins such as sunflower protein, soybean proteins, cotton seed proteins, peanut proteins, grape seed proteins, whey proteins, whey protein isolates, blood proteins, egg proteins, acrylated proteins, water soluble polysaccharides such as alginates, carrageenans, guar gum, agar-agar, xanthan gum, gellan gum, gum arabic and related gums (gum ghatti, gum karaya, gum tragancanth), pectin, water soluble derivatives of cellulose: alkylcelluloses hydroxyalkylcelluloses and
  • hydroxyalkylalkylcelluloses such as methylcellulose, hydroxymethylcellulose,
  • hydroxyalkylcellulose esters such as cellulose acetate phthalate (CAP),
  • HPMC hydroxypropylmethylcellulose
  • carboxyalkylcelluloses
  • carboxyalkylalkylcelluloses such as carboxymethylcellulose and their alkali metal salts
  • water soluble synthetic polymers such as polyacrylic acids and polyacrylic acid esters, polymethacrylic acids and polymethacrylic acid esters,
  • PVAP polyvinylacetatephthalates
  • polyvinylpyrrolidone PVY/vinyl acetate copolymer
  • polycrotonic acids also suitable are phthalated gelatin, gelatin succinate, crosslinked gelatin, shellac, water soluble chemical derivatives of starch, cationically modified acrylates and methacrylates possessing, for example, a tertiary or quaternary amino group, such as the diethylaminoethyl group, which may be quaternized if desired; and other similar polymers.
  • Such extenders may optionally be added in any desired amount desirably within the range of up to about 80%, desirably about 3% to 50% and more desirably within the range of 3% to 20% based on the weight of all components.
  • additives may be inorganic fillers, such as the oxides of magnesium
  • aluminum, silicon, titanium, etc. desirably in a concentration range of about 0.02% to about 3% by weight and desirably about 0.02% to about 1% based on the weight of all components.
  • additives are plasticizers which include polyalkylene oxides, such as polyethylene glycols, polypropylene glycols, polyethylene-propylene glycols, organic plasticizers with low molecular weights, such as glycerol, glycerol monoacetate, diacetate or triacetate, triacetin, polysorbate, cetyl alcohol, propylene glycol, sorbitol, sodium
  • compounds to improve the flow properties of the starch material such as animal or vegetable fats, desirably in their hydrogenated form, especially those which are solid at room temperature. These fats desirably have a melting point of 50 0 C or higher.
  • the mono- and di-glycerides are desirably derived from the types of fats described above, i.e. with Ci 2 -, C 14 -, Ci 6 -, Ci 8 -, C 2 o- and C 22 - fatty acids.
  • the total amounts used of the fats, mono-, di-glycerides and/or lecithins are up to about 5% and preferably within the range of about 0.5% to about 2% by weight of the total composition
  • silicon dioxide calcium silicate, or titanium dioxide in a concentration of about 0.02% to about 1% by weight of the total composition. These compounds act as texturizing agents.
  • additives are to be used in amounts sufficient to achieve their intended purpose. Generally, the combination of certain of these additives will alter the overall release profile of the active ingredient and can be used to modify, i.e. impede or accelerate the release.
  • Lecithin is one surface active agent for use in the present invention. Lecithin can be included in the feedstock in an amount of from about 0.25% to about 2.00% by weight.
  • surface active agents i.e. surfactants
  • surfactants include, but are not limited to, cetyl alcohol, sodium lauryl sulfate, the SpansTM and TweensTM which are commercially available from ICI Americas, Inc.
  • Ethoxylated oils including ethoxylated castor oils, such as Cremophor® EL which is commercially available from BASF, are also useful.
  • CarbowaxTM is yet another modifier which is very useful in the present invention. TweensTM or combinations of surface active agents may be used to achieve the desired hydrophilic-lipophilic balance ("HLB").
  • HLB hydrophilic-lipophilic balance
  • binders which contribute to the ease of formation and general quality of the films.
  • binders include starches, pregelatinize starches, gelatin, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylarnides, polyvinyloxoazolidone, and polyvinylalcohols.
  • solubility enhancing agents such as substances that form inclusion compounds with active components. Such agents may be useful in improving the properties of very insoluble and/or unstable actives. In general, these substances are doughnut-shaped molecules with hydrophobic internal cavities and
  • Insoluble and/or instable actives may fit within the hydrophobic cavity, thereby producing an inclusion complex, which is soluble in water. Accordingly, the formation of the inclusion complex permits very insoluble and/or instable actives to be dissolved in water.
  • a particularly desirable example of such agents are cyclodextrins, which are cyclic carbohydrates derived from starch. Other similar .substances, however, are considered well within the scope of the present invention.
  • the films of the present invention must be formed into a sheet prior to drying.
  • the desired components are combined to form a multi-component matrix, including the polymer, water, and an active or other components as desired
  • the combination is formed into a sheet or film, by any method known in the art such as extrusion, coating, spreading, casting or drawing the multi-component matrix. If a multi-layered film is desired, this may be accomplished by co-extruding more than one combination of components which may be of the same or different composition.
  • a multi-layered film may also be achieved by coating, spreading, or casting a combination onto an already formed film layer.
  • the films of the present invention may be selected of materials that are edible or ingestible. Casting the Film Composition
  • the invention uses processes for making self-supporting films having a substantially uniform distribution of components.
  • the self supporting film is particularly useful for delivery of actives as discussed herein.
  • the processes for making the film are designed to maintain the compositional uniformity of components distributed throughout the film, which is particularly necessary when actives, such as pharmaceutical actives, are incorporated into the film.
  • actives such as pharmaceutical actives
  • it is essential that the film is compositionally uniform so that it can be divided into individual film dosage units, each dosage unit having the appropriate amount of active when administered, such that regulatory approval can be secured.
  • the films are prepared by rapidly forming a visco-elastic film by applying hot air currents to the film to prevent flow migration and intermolecular forces from creating aggregates or conglomerates thereby maintaining compositional uniform distribution of components in the film; and further drying the visco-elastic film to form a self-supporting film.
  • the hot air currents are applied to the bottom of the film, with substantially no top air flow. This allows the depth of the film to be dried prior to forming a polymer skin on the top surface of the film, which would disrupt the surface of the film, leading to non- uniformity.
  • the dried, self-supporting film is uniform in the distribution of the components contained therein, weight and thickness.
  • the film first may be fed onto the top side of a surface prior to the application of hot air currents.
  • the wet film is desirably formed from a deaerated matrix within a time period before the active contained therein degrades.
  • the hot air currents may then be applied to the bottom side of the surface with substantially no top air flow.
  • the process may further include a step of dividing the dried film into individual dosage units of equal dimensions and compositional make-up.
  • the hot air currents may be applied to the bottom surface of the film at a higher velocity than to the top surface of the film during drying. Hot air currents applied to dry the top of the films are less than that which would cause surface rippling or skinning. This permits the film to sufficiently thicken in viscosity to lock-in volumetric uniformity while permitting evaporation of water through the non-skinned surface.
  • the process may further include the preliminary steps of forming a masterbatch premix of an edible water-soluble polymer and water; deaerating the premix by mixing;
  • Coating or casting methods are particularly useful for the purpose of forming the films of the present invention. Specific examples include reverse roll coating, gravure coating, immersion or dip coating, metering rod or meyer bar coating, slot die or extrusion coating, gap or knife over roll coating, air knife coating, curtain coating, or combinations thereof, especially when a multi-layered film is desired.
  • Roll coating or more specifically reverse roll coating, is particularly desired when forming films in accordance with the present invention.
  • This procedure provides excellent control and uniformity of the resulting films, which is desired in the present invention, hi this procedure, the coating material is measured onto the applicator roller by the precision setting of the gap between the upper metering roller and the application roller below it. The coating is transferred from the application roller to the substrate as it passes around the support roller adjacent to the application roller. Both three roll and four roll processes are common.
  • the gravure coating process relies on an engraved roller running in a coating bath, which fills the engraved dots or lines of the roller with the coating material. The excess coating on the roller is wiped off by a doctor blade and the coating is then deposited onto the substrate as it passes between the engraved roller and a pressure roller.
  • Offset Gravure is common, where the coating is deposited on an intermediate roller before transfer to the substrate.
  • the substrate In the simple process of immersion or dip coating, the substrate is dipped into a bath of the coating, which is normally of a low viscosity to enable the coating to' run back into the bath as the substrate emerges.
  • the metering rod coating process an excess of the coating is deposited onto the substrate as it passes over the bath roller.
  • the wire-wound metering rod sometimes known as a Meyer Bar, allows the desired quantity of the coating to remain on the substrate. The quantity is determined by the diameter of the wire used on the rod.
  • the coating In the slot die process, the coating is squeezed out by gravity or under pressure through a slot and onto the substrate.
  • the process is termed "Extrusion” and in this case, the line speed is frequently much faster than the speed of the extrusion. This enables coatings to be considerably thinner than the width of the slot.
  • the gap or knife over roll process relies on a coating being applied to the substrate which then passes through a "gap" between a "knife” and a support roller. As the coating and substrate pass through, the excess is scraped off.
  • Air knife coating is where the coating is applied to the substrate and the excess is "blown off by a powerful jet from the air knife. This procedure is useful for aqueous coatings.
  • a bath with a slot in the base allows a continuous curtain of the coating to fall into the gap between two conveyors.
  • the object to be coated is passed along the conveyor at a controlled speed and so receives the coating on its upper face.
  • the film products of the present invention may be formed by extrusion rather than casting methods. Extrusion is particularly useful for film
  • compositions containing polyethylene oxide-based polymer components ⁇ as discussed below.
  • a single screw extrusion process may be employed in accordance with the present invention.
  • pressure builds in the polymer melt so that it may be extruded through a die or injected into a mold.
  • extrusion methods for forming film compositions containing PEO polymer components.
  • These compositions contain PEO or PEO blends in the polymer component, and may be essentially free of added plasticizers, and/or surfactants, and polyalcohols.
  • compositions may be extruded as a sheet at processing temperatures of less than about 90 0 C. Extrusion may proceed by squeezing the film composition through rollers or a die to obtain a uniform matrix. The extruded film composition then is cooled by any mechanism known to those of ordinary skill in the art. For example, chill rollers, air cooling beds, or water cooling beds may be employed. The cooling step is particularly desirable for film compositions containing PEO polymer components because PEO tends to hold heat.
  • the thus formed sheets can be formed into various shapes, as desired.
  • the drying step is also a contributing factor with regard to maintaining the uniformity of the film composition.
  • a controlled drying process is particularly important when, in the absence of a viscosity increasing composition or a composition in which the viscosity is controlled, for example by the selection of the polymer, the components within the film may have an increased tendency to aggregate or conglomerate.
  • An alternative method of forming a film with an accurate dosage, that would not necessitate the controlled drying process, would be to cast the films on a predetermined well. With this method, although the components may aggregate, this will not result in the migration of the active to an adjacent dosage form, since each well may define the dosage unit per se. When a controlled or rapid drying process is desired, this may be through a variety of methods. A variety of methods may be used including those that require the application of heat.
  • the liquid carriers are removed from the film in a manner such that the uniformity, or more specifically, the non-self-aggregating uniform heterogeneity, that is obtained in the wet film is maintained.
  • the film is dried from the bottom of the film to the top of the film.
  • substantially no air flow is present across the top of the film during its initial setting period, during which a solid, visco-elastic structure is formed. This can take place within the first few minutes, e.g. about the first 0.5 to about 4.0 minutes of the drying process. Controlling the drying in this manner, prevents the destruction and reformation of the film's top surface, which results from conventional drying methods. This is accomplished by forming the film and placing it on the top side of a surface having top and bottom sides. Then, heat is initially applied to the bottom side of the film to provide the necessary energy to evaporate or otherwise remove the liquid carrier.
  • the films dried in this manner dry more quickly and evenly as compared to air-dried films, or those dried by conventional drying means. In contrast to an air-dried film that dries first at the top and edges, the films dried by applying heat to the bottom dry simultaneously at the center as well as at the edges. This also prevents settling of ingredients that occurs with films dried by conventional means.
  • the temperature at which the films are dried is about 100 0 C or less, desirably about 90 0 C or less, and most desirably about 80 0 C or less.
  • the weight of the polar solvent is at least about 30% of the film before drying. In some other embodiments, the drying of the film reduces the weight percent of the polar solvent to about 10% or less. Preferably, the drying occurs within about 10 minutes or fewer.
  • Another method of controlling the drying process which may be used alone or in combination with other controlled methods as disclosed above includes controlling and modifying the humidity within the drying apparatus where the film is being dried. In this manner, the premature drying of the top surface of the film is avoided.
  • the length of drying time can be properly controlled, i.e. balanced with the heat sensitivity and volatility of the components, and particularly the flavor oils and drugs.
  • the amount of energy, temperature and length and speed of the conveyor can be balanced to accommodate such actives and to minimize loss, degradation or ineffectiveness in the final film.
  • An appropriate drying method is that disclosed by Magoon.
  • Magoon is specifically directed toward a method of drying fruit pulp.
  • the present inventors have adapted this process toward the preparation of thin films.
  • the method and apparatus of Magoon are based on an interesting property of water. Although water transmits energy by conduction and convection both within and to its surroundings, water only radiates energy within and to water. Therefore, the apparatus of Magoon includes a surface onto which the fruit pulp is placed that is transparent to infrared radiation. The underside of the surface is in contact with a temperature controlled water bath.
  • the water bath temperature is desirably controlled at a temperature slightly below the boiling temperature of water.
  • the apparatus of Magoon provides the films of the present invention with an efficient drying time reducing the instance of aggregation of the components of the film.
  • a zone drying apparatus may include a continuous belt drying tunnel having one or more drying zones located within.
  • the conditions of each drying zone may vary, for example, temperature and humidity may be selectively chosen. It may be desirable to sequentially order the zones to provide a stepped up drying effect.
  • the speed of the zone drying conveyor desirably is continuous. Alternatively, the speed may be altered at a particular stage of the drying procedure to increase or decrease exposure of the film to the conditions of the desired zone. Whether continuous or modified, the zone drying dries the film without surface skinning.
  • the film 110 may be fed onto the continuous belt 120, which carries the film through the different drying zones.
  • the first drying zone that the film travels through 101 may be a warm and humid zone.
  • the second zone 102 may be hotter and drier, and the third zone 103 may also be hot and dry. These different zones may be continuous, or alternatively, they may be separated, as depicted by the zone drying apparatus 200 in Fig. 10, where the first drying zone 201, second drying zone 202 and third drying zone 203 are shown.
  • the zone drying apparatus in accordance with the present invention, is not limited to three drying zones.
  • the film may travel through lesser or additional drying zones of varying heat and humidity levels, if desired, to produce the controlled drying effect of the present invention,
  • the drying zones may include additional atmospheric conditions, such as inert gases.
  • the zone drying apparatus further may be adapted to include additional processes during the zone drying procedure, such as, for example, spraying and laminating processes, so long as controlled drying is maintained in accordance with the invention.
  • the films may initially have a thickness of about 500 ⁇ m to about 1,500 ⁇ m, or about 20 mils to about 60 mils, and when dried have a thickness from about 3 ⁇ m to about 250 ⁇ m, or about 0.1 mils to about 10 mils.
  • the film product has a thickness of greater than 0.1 mils.
  • the film product has a thickness of about 10 mils or fewer.
  • the film product has a thickness of about 0.5 mils to about 5 mils.
  • the dried films will have a thickness of about 2 mils to about 8 mils, and more desirably, from about 3 mils to about 6 mils. Testing Films for Uniformity
  • films of the present invention may be tested for chemical and physical uniformity during the film manufacturing process, hi particular, samples of the film may be removed and tested for uniformity in film components between various samples. Film thickness and over all appearance may also be checked for uniformity. Uniform films are desired, particularly for films containing pharmaceutical active components for safety and efficacy reasons.
  • a method for testing uniformity in accordance with the present invention includes conveying a film through a manufacturing process. This process may include subjecting the film to drying processes, dividing the film into individual dosage units, and/or packaging the dosages, among others. As the film is conveyed through the manufacturing process, for example on a conveyor belt apparatus, it is cut widthwise into at least one portion. The at least one portion has opposing ends that are separate from any other film portion. For instance, if the film is a roll, it may be cut into separate sub-rolls. Cutting the film may be accomplished by a variety of methods, such as with a knife, razor, laser, or any other suitable means for cutting a film.
  • the cut film then may be sampled by removing small pieces from each of the opposed ends of the portion(s), without disrupting the middle of the portion(s). Leaving the middle section intact permits the predominant portion of the film to proceed through the
  • the manufacturing process may be altered. This can save time and expense because the process may be altered prior to completing an entire manufacturing run.
  • the drying conditions, mixing conditions, compositional components and/or film viscosity may be changed. Altering the drying conditions may involve changing the temperature, drying time, moisture level, and dryer positioning, among others.
  • the thin films of the present invention are well suited for many uses.
  • the high degree of uniformity of the components of the film makes them particularly well suited for incorporating pharmaceuticals.
  • the polymers used in construction of the films may be chosen to allow for a range of disintegration times for the films. A variation or extension in the time over which a film will disintegrate may achieve control over the rate that the active is released, which may allow for a sustained release delivery system.
  • the films may be used for the administration of an active to skin and other body surfaces, including those with mucous membranes.
  • the films may be used to topically administer an active. This is accomplished by preparing the film as described above, introducing the film to a skin surface of a mammal, and wetting the film, for example.
  • this film may be prepared and adhered to a second or support layer from which it is removed prior to use, i.e. application to the skin.
  • An adhesive may be used to attach the film to the support or backing material, which may be any of those known in the art, and is preferably not water soluble. If an adhesive is used, it will desirably be an adhesive that does not alter the properties of the active. Mucoadhesive compositions are also useful. The film compositions in many cases serve as mucoadhesives themselves.
  • the films of the present invention take advantage of the films' tendency to dissolve quickly when wetted.
  • An active may be introduced to a liquid by preparing a film in accordance with the present invention, introducing it to a liquid, and allowing it to dissolve. This may be used to prepare a liquid dosage form of an active, which may then be topically applied.
  • a specific film shape or size may be preferred. Therefore, the film may be cut to any desired shape or size.
  • the films of the present invention are desirably packaged in sealed, air and moisture resistant packages to protect the topical active from exposure oxidation, hydrolysis, volatilization and interaction with the environment.
  • Dosage unit 10 includes each film 12 individually wrapped in a pouch or between foil and/or plastic laminate sheets 14.
  • the pouches 10, 10' can be linked together with tearable or perforated joints 16.
  • the pouches 10, lO' may be packaged in a roll as depicted in Figure 5 or stacked as shown in Figure 3 and sold in a dispenser 18 as shown in Figure 4.
  • the dispenser may contain a full supply of the medication typically prescribed for the intended therapy, but due to the thinness of the film and package, is smaller and more convenient than traditional bottles used for tablets, capsules and liquids.
  • the films of the present invention dissolve instantly with a wetting agent, such as water, or by contact with mucosal membrane areas.
  • a wetting agent permits a topical active agent contained within the film to be dissolved or dispersed out of the film. The topical agent may then be easily applied to the skin or other particular surface area.
  • a series of such unit doses are packaged together in accordance with the prescribed regimen or treatment, e.g., a 10-90 day supply, depending on the particular therapy.
  • the individual films can be packaged on a backing and peeled off for use.
  • the present example is directed to the incorporation of a skin care cream into a polyethylene oxide/hydroxypropylmethyl cellulose (70/30) film base.
  • the skin care cream used in this example is an emulsion composition.
  • the resulting film was found to be useful as a dissolvable skin lotion film (22.38% solids, by weight).
  • the components are shown below in Table A.
  • the solution was cast into film using the K-Control Coater with the micrometer adjustable wedge bar set at 450 microns onto the HDP side of 6330, coated side of 6330 and 55 # PS/1 /5 "IN" release paper (Griff, Fallsington, PA).
  • the film was dried 15 minutes in an 80 0 C air oven to about 3.50% moisture (HR 73 Moisture Analyzer).
  • the film released readily from all substrates.
  • the resulting film had a thickness of 2.8 mils, had good tear resistance, had sufficient strength when pulled, was not sticky, and. passed the 180° bend test out of the moisture analyzer.
  • a piece of the film when wetted in the hand with water, dissolved readily, leaving the skin care cream which spread on the skin easily.
  • the emulsion reformed when the film was contacted with water.
  • the present example demonstrates the feasibility of preparing a dissolvable skin lotion film.
  • the film was cut into 1 1 A inch by 2 ! ⁇ inch strips, which each weighed 148 mg, demonstrating the uniformity of the composition of the film.
  • the present example is directed to the incorporation of a sunscreen into a
  • polyethylene oxide/hydroxypropylmethyl cellulose (70/30) film base The sunscreen used in this example is an emulsion composition.
  • the resulting film was found to be useful as a dissolvable sunscreen lotion film (22% solids, by weight).
  • the components of the film are shown below in Table C. TABLE C
  • the sunscreen and sorbitan monooleate from Table C were combined with 31.04g of distilled water and added to a Degussa 1100 bowl. Then, a blend of the polyethylene oxide and hydroxypropylmethyl cellulose was added to the bowl. The combination of components was mixed using the Degussa Dental Multivac Compact under the same conditions as described in Table B of Example 1.
  • the resulting solution was cast into film using the K-Control Coater with the micrometer adjustable wedge bar set at 450 microns onto the HDP side of 6330.
  • the film was dried 15 minutes in an 80°C air oven.
  • the film had 2.94% of moisture (HR73 Moisture Analyzer).
  • the resulting film had a thickness of 3 mil, showed some mottling on surface, showed curling, had good tear resistance and had a film adhesion rating of 5 from the HDP side of 6330. It also had sufficient strength when pulled, was not sticky and passed the 180° bend test out of the moisture analyzer.
  • the film was cut into 1 1 A inch by 2Kz inch pieces, each weighting 152 mg.
  • a piece of the film when wetted in the hand, dissolved readily and left the sunscreen, which spread on the skin easily.
  • the sunscreen emulsion reformed when the film was dissolved with water.
  • the present example is directed to the incorporation of an antibacterial soap (Equate brand) into a polyethylene oxide / hydroxypropylmethyl cellulose (70/30) film base for use as a dissolvable soap film (22% solids, by weight).
  • an antibacterial soap Equate brand
  • a polyethylene oxide / hydroxypropylmethyl cellulose (70/30) film base for use as a dissolvable soap film (22% solids, by weight).
  • the components of the film are shown below in Table D. TABLE D
  • Equate brand containing: 1.32g (15%) active and other ingredients; and 8.3g water.
  • the antibacterial soap and sorbitan monooleate were combined with 22.9g distilled water in a Degussa 1100 bowl. Then, a blend of the polyethylene oxide and
  • hydroxypropylmethyl cellulose was added to the bowl.
  • the combination of components was mixed using the Degussa Dental Multivac Compact under the conditions set forth in Table E below.
  • the resulting solution was cast into film using the K-Control Coater with micrometer adjustable wedge bar set at 450 microns onto the HDP side of 6330, coated side of 6330, and 55 " # PS/1/5 'TN" release paper (Griff).
  • the film was dried 15 minutes in an 80 0 C air oven to about 1.60% moisture (HR73 Moisture Analyzer).
  • the resulting film had a thickness of 4.5 mils, had a film adhesion rating of 6 from HDP side of 6330 and came loose from all substrates. It also had moderate tear resistance, had adequate strength when pulled, was not sticky, and passed the 180° bend test out of the moisture analyzer.
  • a 114 inch x 214 inch piece of film weighed 150 mg.
  • the present example is directed to the incorporation of a shampoo into a polyethylene oxide / hydroxypropylmethyl cellulose (70/30) film base.
  • the shampoo used in this example is an emulsion composition.
  • the resulting film was found to be useful as a dissolvable shampoo film strip (22% solids, by weight).
  • the components of the film are shown below in Table F.
  • the menthol component and 25.26g of distilled water were placed in a Degussa 1100 bowl. Then, a blend of the polyethylene oxide and hydroxypropylmethyl cellulose was added to the bowl. A solution was prepared as described below in Table G using the Degussa Dental Multivac Compact.
  • the shampoo was added to the solution, and mixing continued for an additional 4 minutes at 100 rpm, under vacuum (28 Hg).
  • the resulting solution was cast into film using the K-Control Coater with the micrometer adjustable wedge bar set at 450 microns onto the HDP side of 6330.
  • the film was dried 15 minutes in an 80 0 C air oven.
  • the film had a thickness of 3.4 mils and had a film adhesion of 5 from the HDP side of 6330. It also had moderate tear resistance, had good strength when pulled, was not sticky, and passed the 180° bend test out of the moisture analyzer.
  • a l !4 inch x 2 ⁇ ⁇ inch strip weighed 162 mg. When wetted in the hand, this strip dissolved fairly well and left the shampoo which lathered. In particular, the emulsion reformed when the film was dissolved with water.
  • a liquid dish soap is incorporated into a polyethylene oxide / polydextrose (80/20) film base.
  • the dissolvable soap film strip contained 25% solids by weight. The components of the film are shown below in Table H.
  • a blend of polyethylene oxide and polydextrose was added to a D.egussa 1 100 bowl, along with 29.08g of distilled water.
  • a solution was prepared, as described below in Table I using the Degussa Dental Multivac Compact.
  • the liquid dish detergent component was added to the bowl, and mixing continued for another 4 minutes at 125 rpm under vacuum (28 Hg).
  • the resulting solution was cast into film using the K-Control Coater with the micrometer adjustable wedge bar set at 450 microns onto the HDP side and coated side of 6330.
  • the film was dried for 15 minutes in an 80 0 C air oven.
  • the film had a moisture content of 3.85% (HR 73 Moisture Analyzer).
  • the film had a thickness of 3 mils, had a film adhesion rating of 4 from the HDP side of 6330, and had good tear resistance. It also had adequate strength when pulled, was not sticky and passed the 180° bend test out of the moisture analyzer.
  • a I 1 A inch x IVi inch strip of the film weighted 168 mg. The film strips dissolved readily in water, and produced soap suds. However, the soap level was not sufficient. Therefore, a higher level of soap would be needed. As shown below in Example 5B, incorporating a higher level of soap into the same film base produced a film that was found to be useful as a dissolvable dish detergent film.
  • the present example is directed to the incorporation of a concentrated liquid dish detergent into a polyethylene oxide / polydextrose (80/20) film base.
  • the resulting film as found to be useful as a dissolvable dish detergent film (35% solids, by weight).
  • the components of the film are shown below in Table J.
  • Distilled water (26.75g) was placed in a Degussa 1100 bowl. Then, a blend of polyethylene oxide and polydextrose was added to the bowl. A solution was prepared as described below in Table K, using a Degussa Dental Multivac Compact. TABLE K
  • the liquid dish detergent was added to the bowl, and mixing continued for an additional 2 minutes at 100 rpm under vacuum at 24 Hg.
  • the resulting solution was cast into film using the K-Control Coater with the micrometer adjustable wedge bar set at 500 microns onto the HDP side of 6330.
  • the film was dried for 15 minutes in an 80 0 C air oven.
  • the moisture content in the film was 4.78% (HR 73 Moisture Analyzer).
  • the film had a film adhesion rating of 9 from the HDP side of 6330, had excellent tear resistance, had adequate strength when pulled, was not tacky, and passed the 180° bend test out of the moisture analyzer.
  • a 4 inch by 2.75 inch strip of the film weighed 5.79 mg. The film strip dissolved readily when contacted with water, and gave sufficient suds for dish washing.
  • the present example is directed to incorporation of an antibacterial hand soap into a polyethylene oxide / hydroxypropylmethyl cellulose (70/30) film base.
  • the film is to be used as a dissolvable hand soap film. (22% solids, by weight).
  • the components of the film are shown below in Table L.
  • Ultra Dawn Antibacterial Hand Soap containing: 1.76g (20%) of active and other ingredients; and 1. Ig water.
  • the menthol and 30. Ig of distilled water were placed in aDegussa 1100 bowl. Then, a blend of the polyethylene oxide and hydroxypropylmethyl cellulose was added to the bowl.
  • a solution was prepared as described in Table M using the Degussa Dental Multivac Compact.
  • the resulting solution was cast into film using the K-Control Coater with the micrometer adjustable wedge bar set at 450 microns onto the HDP side of 6330, and coated side of 6330.
  • the film was dried for 15 minutes in an 80 0 C air oven.
  • the percent moisture of the film was 2.6% (HR73 Moisture Analyzer).
  • the film had a thickness of 3 mils, came loose from both substrates, had a film adhesion rating of 5 from HDP side of 6330 and had moderate tear resistance. It also had good strength when pulled, was not sticky, and passed the 180° bend test out of the moisture analyzer.
  • a VA inch x 2 1 A inch strip weighed 153 mg.
  • the present example is directed to the incorporation of a prilocaine/lidocaine (50/50) eutectic into a PEO/hydroxypropylmethyl cellulose/polydextrose (70/10/20) film base at the 50 mg dose level in a 110 mg strip. Droplets of eutectic oil are captured in the film base during the drying of the film.
  • the film base when wetted, is useful as a dispersion of a prilocaine/lidocaine eutectic.
  • the prilocaine/lidocaine eutectic is an oil at room temperature and therefore permits better skin penetration than the corresponding salt forms.
  • the HCl salt of prilocaine was neutralized with NaOH according to the following reaction, which was performed in situ, as described in further detail below:
  • the resulting solution was cast into film using the K-Control Coater with the micrometer adjustable wedge bar set at 550 microns onto the HDP side of 6330.
  • the film was dried 17 minutes in an 80 0 C oven to about 2.83% moisture.
  • the film was cut into VA x 1 inch strips, which weighed 107 mg.
  • the resulting film was a dry film which contained a dispersion of the eutectic oil, as observed under the microscope. This observation was made when water was added to the film, as further described below.
  • the dry film had excellent tear resistance, was only slightly sticky and had adequate strength when pulled. It also had a film adhesion rating of 6 from the HDP side of 6330, and cut satisfactorily with die.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L’invention concerne des films et leurs procédés de fabrication, lesdits films présentant une hétérogénéité uniforme non susceptible de s’auto-agglomérer. Il est préférable que les films se désintègrent dans l’eau. Ils peuvent être formés par un procédé de séchage contrôlé ou par d'autres procédés qui maintiennent l'uniformité requise du film. Il est préférable que les films contiennent un agent actif topique.
PCT/US2006/046269 2005-12-06 2006-12-05 Compositions de films topiques pour la liberation d’actifs WO2007067494A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002630261A CA2630261A1 (fr) 2005-12-06 2006-12-05 Compositions de films topiques pour la liberation d'actifs
JP2008544421A JP2009518405A (ja) 2005-12-06 2006-12-05 活性物質の送達のための局所フィルム組成物
EP06844795A EP1971312A1 (fr) 2005-12-06 2006-12-05 Compositions de films topiques pour la liberation d actifs
AU2006322050A AU2006322050A1 (en) 2005-12-06 2006-12-05 Topical film compositions for delivery of actives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74277605P 2005-12-06 2005-12-06
US60/742,776 2005-12-06

Publications (1)

Publication Number Publication Date
WO2007067494A1 true WO2007067494A1 (fr) 2007-06-14

Family

ID=37945449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046269 WO2007067494A1 (fr) 2005-12-06 2006-12-05 Compositions de films topiques pour la liberation d’actifs

Country Status (6)

Country Link
EP (1) EP1971312A1 (fr)
JP (1) JP2009518405A (fr)
CN (1) CN101321511A (fr)
AU (1) AU2006322050A1 (fr)
CA (1) CA2630261A1 (fr)
WO (1) WO2007067494A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006210A1 (fr) * 2007-06-29 2009-01-08 Union Carbide Chemicals & Plastics Technology Llc Coiffure et films de soins personnels de conditionnement capillaire
WO2009006214A1 (fr) * 2007-06-29 2009-01-08 Union Carbide Chemicals & Plastics Technology Llc Films solubles de soin d'hygiène personnelle
WO2009006218A3 (fr) * 2007-06-29 2009-06-11 Union Carbide Chem Plastic Films solubles de soins d'hygiène personnelle
JP2011521975A (ja) * 2008-05-30 2011-07-28 オリエント ファーマ シーオー．，エルティーディー． 医薬化合物の経皮送達のための組成物と方法
US8652378B1 (en) 2001-10-12 2014-02-18 Monosol Rx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8846074B2 (en) 2010-12-16 2014-09-30 Cynapsus Therapeutics, Inc. Sublingual films
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8906277B2 (en) 2001-10-12 2014-12-09 Monosol Rx, Llc Process for manufacturing a resulting pharmaceutical film
US9044475B2 (en) 2009-06-12 2015-06-02 Cynapsus Therapeutics, Inc. Sublingual apomorphine
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US9192550B2 (en) 2010-06-22 2015-11-24 Avon Products, Inc. Magnetically-oriented cosmetic fibers
WO2015107544A3 (fr) * 2013-12-17 2015-11-26 Zim Laboratories Limited Microémulsion pharmaceutique immobilisée dans une matrice polymère mince et ses procédés de fabrication
EP3041357A1 (fr) * 2013-09-04 2016-07-13 Stiftelsen Arcada Surfaces demeurant exemptes d'organismes microbiologiques
WO2019058397A1 (fr) * 2017-09-21 2019-03-28 Jubeln Lifesciences, Pvt. Ltd. Formulation et développement de film topique ou transdermique
US10272607B2 (en) 2010-10-22 2019-04-30 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US10449146B2 (en) 2015-04-21 2019-10-22 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US10744086B2 (en) 2009-10-30 2020-08-18 Ix Biopharma Ltd. Fast dissolving solid dosage form
US10821074B2 (en) 2009-08-07 2020-11-03 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
CN113149023A (zh) * 2021-03-11 2021-07-23 昆明理工大学 一种介孔二氧化硅纳米颗粒经皮递送低共熔体系制备方法
US11077068B2 (en) 2001-10-12 2021-08-03 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN116098882A (zh) * 2023-04-06 2023-05-12 山东诚创蓝海医药科技有限公司 一种含利多卡因丙胺卡因的组合物及其制备方法
US11648197B2 (en) 2018-06-28 2023-05-16 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2448553A2 (fr) * 2009-06-30 2012-05-09 Dow Global Technologies LLC Films dissolvables contenant un écran solaire
US8974826B2 (en) * 2010-06-10 2015-03-10 Monosol Rx, Llc Nanoparticle film delivery systems
WO2012170828A1 (fr) * 2011-06-10 2012-12-13 Monosol Rx, Llc Combinaison peptide-nanoparticules et systèmes d'administration l'incorporant
JP2014214133A (ja) * 2013-04-26 2014-11-17 日立化成株式会社 ナノ薄膜転写シート製品の製造方法及びその転写方法
JP6315754B2 (ja) * 2013-10-02 2018-04-25 花王株式会社 シート状化粧料
US10982175B2 (en) * 2017-03-30 2021-04-20 Dow Global Technologies Llc Free standing film

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
WO2002005789A2 (fr) * 2000-07-15 2002-01-24 Scs Skin Care Systems Gmbh Feuille contenant des produits dermatologiques
WO2002043657A2 (fr) * 2000-11-30 2002-06-06 Wm. Wrigley Jr. Company Preparations comestibles exemptes de pullulane, ameliorees et economiques et leur procede d'obtention
US6419906B1 (en) * 2001-03-12 2002-07-16 Colgate Palmolive Company Strip for whitening tooth surfaces
WO2004087084A1 (fr) * 2003-03-26 2004-10-14 The Procter & Gamble Company Compositions de films comestibles a dissolution rapide avec des polymeres filmogenes cellulosiques
WO2005074867A1 (fr) * 2004-01-21 2005-08-18 L'oreal Film anhydre pour le maquillage ou le soin des levres.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
EP1463491B1 (fr) * 2001-10-12 2012-09-12 MonoSolRX, LLC Film mince pourvu d'une heterogeneite uniforme non autoagglomerante, son procede d'elaboration et systemes d'administration de medicaments ainsi produits
MXPA02011337A (es) * 2001-11-16 2003-05-26 Nat Starch Chem Invest Peliculas que contienen almidon.
JP2004043450A (ja) * 2002-05-16 2004-02-12 Kyukyu Yakuhin Kogyo Kk 速溶性フィルム状製剤
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
WO2002005789A2 (fr) * 2000-07-15 2002-01-24 Scs Skin Care Systems Gmbh Feuille contenant des produits dermatologiques
WO2002043657A2 (fr) * 2000-11-30 2002-06-06 Wm. Wrigley Jr. Company Preparations comestibles exemptes de pullulane, ameliorees et economiques et leur procede d'obtention
US6419906B1 (en) * 2001-03-12 2002-07-16 Colgate Palmolive Company Strip for whitening tooth surfaces
WO2004087084A1 (fr) * 2003-03-26 2004-10-14 The Procter & Gamble Company Compositions de films comestibles a dissolution rapide avec des polymeres filmogenes cellulosiques
WO2005074867A1 (fr) * 2004-01-21 2005-08-18 L'oreal Film anhydre pour le maquillage ou le soin des levres.

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931305B2 (en) 2001-10-12 2018-04-03 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8652378B1 (en) 2001-10-12 2014-02-18 Monosol Rx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US9855221B2 (en) 2001-10-12 2018-01-02 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10888499B2 (en) 2001-10-12 2021-01-12 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US11077068B2 (en) 2001-10-12 2021-08-03 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8906277B2 (en) 2001-10-12 2014-12-09 Monosol Rx, Llc Process for manufacturing a resulting pharmaceutical film
US10111810B2 (en) 2002-04-11 2018-10-30 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
JP2010532375A (ja) * 2007-06-29 2010-10-07 ユニオン カーバイド ケミカルズ アンド プラスティックス テクノロジー エルエルシー パーソナルケア溶解性フィルム
WO2009006210A1 (fr) * 2007-06-29 2009-01-08 Union Carbide Chemicals & Plastics Technology Llc Coiffure et films de soins personnels de conditionnement capillaire
CN101686926B (zh) * 2007-06-29 2012-10-10 联合碳化化学品及塑料技术公司 头发定型和调理个人护理膜
WO2009006214A1 (fr) * 2007-06-29 2009-01-08 Union Carbide Chemicals & Plastics Technology Llc Films solubles de soin d'hygiène personnelle
WO2009006218A3 (fr) * 2007-06-29 2009-06-11 Union Carbide Chem Plastic Films solubles de soins d'hygiène personnelle
JP2011521975A (ja) * 2008-05-30 2011-07-28 オリエント ファーマ シーオー．，エルティーディー． 医薬化合物の経皮送達のための組成物と方法
US9326981B2 (en) 2009-06-12 2016-05-03 Cynapsus Therapeutics, Inc. Sublingual apomorphine
US9044475B2 (en) 2009-06-12 2015-06-02 Cynapsus Therapeutics, Inc. Sublingual apomorphine
US9669020B2 (en) 2009-06-12 2017-06-06 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
US9669021B2 (en) 2009-06-12 2017-06-06 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
US9669018B2 (en) 2009-06-12 2017-06-06 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
US9669019B2 (en) 2009-06-12 2017-06-06 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
US10420763B2 (en) 2009-06-12 2019-09-24 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
US10821074B2 (en) 2009-08-07 2020-11-03 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11975097B2 (en) 2009-10-30 2024-05-07 Ix Biopharma Ltd. Fast dissolving solid dosage form
US10744086B2 (en) 2009-10-30 2020-08-18 Ix Biopharma Ltd. Fast dissolving solid dosage form
US9192550B2 (en) 2010-06-22 2015-11-24 Avon Products, Inc. Magnetically-oriented cosmetic fibers
US10272607B2 (en) 2010-10-22 2019-04-30 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10940626B2 (en) 2010-10-22 2021-03-09 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US9283219B2 (en) 2010-12-16 2016-03-15 Cynapsus Therapeutics, Inc. Sublingual films
US10285953B2 (en) 2010-12-16 2019-05-14 Sunovion Pharmaceuticals Inc. Sublingual films
US8846074B2 (en) 2010-12-16 2014-09-30 Cynapsus Therapeutics, Inc. Sublingual films
US11419769B2 (en) 2010-12-16 2022-08-23 Sunovion Pharmaceuticals Inc. Sublingual films
US9427412B2 (en) 2010-12-16 2016-08-30 Cynapsus Therapeutics, Inc. Sublingual films
US10588314B2 (en) 2013-09-04 2020-03-17 Stiftelsen Arcada Surfaces which stay microbiologically clean
EP3041357A1 (fr) * 2013-09-04 2016-07-13 Stiftelsen Arcada Surfaces demeurant exemptes d'organismes microbiologiques
US10660862B2 (en) 2013-12-17 2020-05-26 Zim Laboratories Limited Pharmaceutical microemulsion immobilized in a thin polymer matrix and methods of making them
WO2015107544A3 (fr) * 2013-12-17 2015-11-26 Zim Laboratories Limited Microémulsion pharmaceutique immobilisée dans une matrice polymère mince et ses procédés de fabrication
US10959943B2 (en) 2015-04-21 2021-03-30 Sunovion Pharmaceuticals Inc. Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
US10449146B2 (en) 2015-04-21 2019-10-22 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12023309B2 (en) 2016-05-05 2024-07-02 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
WO2019058397A1 (fr) * 2017-09-21 2019-03-28 Jubeln Lifesciences, Pvt. Ltd. Formulation et développement de film topique ou transdermique
US11648197B2 (en) 2018-06-28 2023-05-16 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
CN113149023B (zh) * 2021-03-11 2023-05-02 昆明理工大学 一种介孔二氧化硅纳米颗粒经皮递送低共熔体系制备方法
CN113149023A (zh) * 2021-03-11 2021-07-23 昆明理工大学 一种介孔二氧化硅纳米颗粒经皮递送低共熔体系制备方法
CN116098882A (zh) * 2023-04-06 2023-05-12 山东诚创蓝海医药科技有限公司 一种含利多卡因丙胺卡因的组合物及其制备方法

Also Published As

Publication number Publication date
EP1971312A1 (fr) 2008-09-24
JP2009518405A (ja) 2009-05-07
AU2006322050A1 (en) 2007-06-14
CN101321511A (zh) 2008-12-10
CA2630261A1 (fr) 2007-06-14

Similar Documents

Publication Publication Date Title
US20200146997A1 (en) Films and drug delivery systems made therefrom
US9931305B2 (en) Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20070154527A1 (en) Topical film compositions for delivery of actives
WO2007067494A1 (fr) Compositions de films topiques pour la liberation d’actifs
US20190380973A1 (en) Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7910641B2 (en) PH modulated films for delivery of actives
CA2544776C (fr) Films a base d'oxyde de polyethylene et systemes d'administration de medicaments en etant faits
US9108340B2 (en) Process for manufacturing a resulting multi-layer pharmaceutical film
US20080050422A1 (en) Method of administering a film product containing a drug
CA2514897C (fr) Film mince a heterogeneite uniforme non auto-agglomerante et systemes d'administration de medicaments a base dudit film
US20140008831A1 (en) Films and Drug Delivery Systems Made Therefrom
US20080292683A1 (en) Film shreds and delivery system incorporating same
US20110166240A1 (en) Ph modulated films for delivery of actives
US20140070440A1 (en) Films and Drug Delivery Systems Made Therefrom
US20090297585A1 (en) pH Modulated Films for Delivery of Actives
US20100021526A1 (en) Ph modulated films for delivery of actives
AU2012261557A1 (en) Polyethylene oxide-based films and drug delivery systems made therefrom

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680045517.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2630261

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006322050

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008544421

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2467/KOLNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006322050

Country of ref document: AU

Date of ref document: 20061205

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006844795

Country of ref document: EP